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Abstract 
BRINGING TIL THERAPY BEYOND MELANOMA: ADVANCING THE TREATMENT 
OF ADVANCED PANCREATIC AND OVARIAN CANCERS 
Donald Sakellariou-Thompson, B.S. 
Advisory Professors: Chantale Bernatchez, Ph.D. 
                      Patrick Hwu, M.D. 
 
The success of checkpoint blockade immunotherapy (CBI) has reinvigorated the cancer 
therapy field, particularly for advanced melanoma which has doubled the survival rates 
compared to 20 years ago. However, there are many solid tumor types that are yet to receive 
substantial benefit from this ground breaking therapy, two of which are pancreatic cancer 
(PDAC) and ovarian cancer (OvCa). As such, the 5-year survival rate for PDAC and OvCa 
stand at 9% and 28% respectively. Despite the lack of efficacy of CBI so far, there is still 
evidence for the role of immune control in these cancers as evidenced by presence of tumor-
infiltrating lymphocytes (TIL) correlating with increased survival. Since in vivo manipulation 
of TIL through CBI does not seem to be sufficient to generate a strong clinical response, 
approaches involving ex vivo manipulation of immune cells, such as adoptive cell therapy 
(ACT) using autologous TIL, might be able to provide therapeutic benefit. The effectiveness 
of TIL ACT has been demonstrated in metastatic melanoma with overall response rates 
around 50%. Given this success and the anti-tumor potential of the immune infiltrate in 
PDAC and OvCa, I sought to assess the feasibility of TIL ACT in these solid tumors. My 
work here has demonstrated the feasibility of TIL ACT for PDAC and OvCa by showing that 
they harbor an activated, anti-tumor CD8+ T-cell infiltrate that can be robustly and reliably 
expanded using an improved 3-signal culture method consisting of a CD3 stimulation, an 
vi 
 
agonistic 4-1BB mAb, and high-dose IL-2. Additionally, these results show that TIL ACT for 
PDAC and OvCa is viable regardless of primary or metastatic site and regardless of prior 
chemotherapy. Furthermore, given the difficulty of treating PDAC, single-cell RNA 
sequencing was used to interrogate the immune landscape to further our understanding of the 
TIL heterogeneity in PDAC. Paired transcriptomic and T-cell receptor sequencing revealed 
novel TIL populations with potential prognostic and therapeutic implications. A Phase II 
clinical trial based on this work has been initiated at MDACC to evaluate the feasibility of 
the adoptive transfer of autologous TIL in recurrent or refractory PDAC and OvCa 
(NCT03610490). 
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Chapter 1: Introduction 
 
The immune system is the body’s main defense mechanism against disease and this 
protection is mediated by a complex system of specialized cells and molecules. Although its 
major mechanisms were only elucidated within the last 150 years, the concept of immunity 
has been known, at least implicitly, since the time of Ancient Greece when it was observed 
that only those people who had survived the plague could take care of the sick because they 
would not contract the disease again [1]. In the 18th and 19th centuries, work by Edward 
Jenner, Louis Pasteur, Robert Koch, Emil von Behring, Shibasaburo Kitasato, and Jules 
Bordet provided empirical evidence for immunity [1]. However, major mechanisms of the 
immune system were not revealed until observations by Elie Metchnikoff and Paul Ehrlich. 
Metchnikoff discovered that there were phagocytic cells, which he termed macrophages, 
which were always present in order to respond and clear pathogenic microorganisms. 
Ehrlich’s research established the idea that neutralizing antibodies could be induced against a 
wide array of foreign substances named antigens. Fittingly, the importance of their work was 
recognized with the Nobel Prize in 1908. Since then, the importance of this work has only 
grown as improved understanding of the mechanisms of the immune system has allowed for 
the ability to harness its potential for treating disease. In this context, the disease that looms 
large for many people is cancer in all its various forms. The Word Health Organization 
estimates that the global cancer burden has risen to 18 million new cases with 9.6 million 
deaths in 2018 [2]. In this introductory chapter, I intend to lay out (1) the relationship 
between the immune system and cancer, (2) provide an overview of how the current 
understanding of this relationship has led to the immunotherapy revolution in cancer 
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treatment, with particular focus on (3) a type of immunotherapy involving the adoptive 
transfer of tumor-infiltrating T cells and (4) our efforts to improve and expand its application.  
 
1.1: The Immune System and Cancer 
 
Metchnikoff and Ehrlich’s work laid the foundation for the two major compartments 
of the immune system, innate immunity and adaptive immunity, which work in concert to 
protect the body from foreign pathogens. All blood cells derive from stem cells in the bone 
marrow, called pluripotent hematopoietic stem cells (HSCs), including the components of the 
innate and adaptive immune system (Figure 1). The major cellular elements of both will be 
discussed below in order to lay a foundation for how the actions of the immune system are 
mediated.  
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Bone marrow-derived hematopoietic stem cells give rise to the common myeloid and 
lymphoid progenitor cell, which themselves differentiate into the major cellular components 
of the immune system. 
 
1.1.1 Innate Immunity   
Innate immunity is the first line of defense, and it is responsible for non-specific but 
immediate responses that can feed into adaptive immunity. This consists of several 
components, but the main and largest one that I will highlight is the myeloid cellular 
component. Myeloid cells arise from the common myeloid progenitor cell (CMP), which 
itself originates from bone marrow HSCs [1]. Along with the macrophages first described by 
Metchnikoff, the myeloid component is comprised of other phagocytic cells like dendritic 
cells and several kinds of granulocytes. While having the similar property of engulfing 
pathogens, they also have other important functions that are briefly described below: 
Macrophages. One of the blood cell types that arises from CMPs following 
differentiation from HSCs are monocytes, which circulate in the blood before entering 
various tissues and maturing into macrophages. These cells are the main phagocytic cell (i.e. 
they engulf pathogens) in the body and are found in most tissues trawling for foreign 
microorganisms to clear. Macrophages also participate in initiating larger immune responses 
by producing inflammatory mediators and by functioning as antigen presenting cells (APCs). 
APCs present antigens to the effector cells of the immune system using a class of surface 
receptor known as the major histocompatibility complex (MHC; also known as Human 
Leukocyte Antigen [HLA]). Antigen presentation is a highly integral part of bridging the 
innate and adaptive immune responses which will be discussed further in section 1.1.5.  
Figure 1. Hematopoietic stem cell differentiation.  
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Dendritic cells.  Also deriving from the CMP, immature dendritic cells (DCs) exit 
the bone marrow into circulation and enter various tissues, such as the skin or gastrointestinal 
tract, constantly checking for pathogens. While DCs have phagocytic capacity as well, they 
also constantly sample material from the extracellular space, process it internally, and present 
small pieces of this material, known as antigens, on their surface. If a DC becomes activated 
during this process, it will migrate from the tissue to the nearest lymph node to interface with 
adaptive immune cells. This process allows them to perform their main and most important 
function as an APC.  
Granulocytes. The third major cell population that arises from the CMP is the 
granulocytes, which consists of neutrophils, eosinophils, basophils, and mast cells. They are 
named granulocytes due to the many granules of degradative enzymes they secrete or use to 
breakdown phagocytosed pathogens. Neutrophils are the most abundant granulocyte (60-70% 
of white blood cells) and are a major responder to infection. Eosinophils, basophils, and mast 
cells are less abundant and mainly respond to parasites as well as allergic reactions. All 
provide a very fast response (minutes) and are short-lived.  
The components of the innate immune system are often called sensor cells because 
they express receptors that allow them to detect various inflammatory mediators. These 
innate receptors are called pattern recognition receptors (PRRs) because the recognize 
molecules common to various pathogens or indicators of cell stress. Unlike the lymphocyte 
receptors that will be described in the following section, these innate receptors do not have a 
highly variable repertoire of specificities.  
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1.1.2 In between innate and adaptive immunity 
Two other cell types worth mentioning with regard to innate and adaptive immunity 
are the natural killer (NK) cell and the gamma-delta (γδ) T cell.  While these cells derive 
from the CLP and are considered lymphocytes, they do not possess the hypervariable antigen 
receptors that define B cells and T cells [1]. These cells can be thought of as occupying a 
transitional space between innate and adaptive immunity due to sharing characteristics of 
both systems. They are briefly described below: 
NK cells. Although it is a lymphoid cell, NK cells also display several characteristics 
of innate immune cells. They lack hypervariable antigen-specific receptors and instead 
express several types of innate receptors that allow them to quickly respond to cellular stress 
or infection. They are also able to recognize and destroy antibody-coated pathogens via Fc 
receptors which recognize the “base” of antibodies (Figure 2A). As such, NK cells bypass the 
need for antigen recognition in the context of MHC, and in fact will also target cells that do 
not express MHC. Additionally, recent findings suggest that they have most features of 
adaptive immunity except for the antigen-specific receptors. As such it has been proposed 
that they occupy the evolutionary space between innate and adaptive immunity [3].  
γδ T cell. This type of T cell is defined by expression of distinctive, invariant TCRs 
that is composed of a TCRγ and TCRδ chain, hence the name. While γδ T cells have many 
phenotypic and functional similarities to αβ T cells, the difference in TCR allows them 
recognize antigens directly on the surface of target cells, outside of the context of MHC. 
They also have a much more limited repertoire of antigen specificity and may even function 
similarly to an innate immune cell in terms of pattern recognition. The complete role of γδ T 
cells and their antigen targets are still being elucidated. 
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1.1.3 Adaptive immunity  
Ehrlich’s work, among others, hinted at the existence and function of adaptive 
immunity. This system is composed of highly specialized cells, called lymphocytes, which 
arise from the common lymphoid progenitor (CLP) in the bone marrow [1]. Each of these 
lymphocytes express antigen receptors with a specificity unique to each cell (Figure 2). 
When these cells divide, the unique antigen receptor will be passed on to the daughter cells 
which are often referred to as clones due to sharing the unique receptor. This diverse 
repertoire of antigen specificity is what allows the immune system to ultimately respond to 
almost any challenge. The hypervariability of these antigen receptors is accomplished 
through random genetic recombination of several hundred gene segments to generate a 
seemingly infinite range of specificities. The two main lymphocyte cell types are described 
below: 
 
7 
 
 
Figure 2. Structure and function of B- and T-cell antigen receptors.  
(A) The B-cell receptor is a Y-shaped protein consisting of two chains. At the forked-end of 
the Y is the variable region where the receptor binds its cognate antigen. After a B cell is 
activated, it beings to secrete its receptor in the form antibodies. These bind to their targets in 
order to neutralize or mark them for clearance. (B) The T-cell receptor consists of two 
chains, the most common pairing being the alpha- and beta-chains. The T-cell becomes 
activated after recognizing its antigen in the context of MHCI, which is generally on the 
surface of a dendritic cell. After activation, the T cell will traffic through the body until it 
again recognizes its target on the surface of a tumor cell and destroy the target cell.  
  
B lymphocytes. Also known as B cells, these lymphocytes are white blood cells that 
differentiate from the CLP in the bone marrow and then circulate in the peripheral blood as 
well as reside in lymph nodes.  As mentioned, each express a unique antigen receptor (the B 
cell receptor or BCR) that is essentially a membrane-bound antibody. Upon recognition of an 
antigen via their BCR, B cells become activated and secrete Y-shaped proteins called 
antibodies with the same specificity as the BCR (Figure 2A). These antibodies can bind to 
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targets to either neutralize them directly or mark them for clearance by innate immune cells 
like macrophages. Therefore, B cells are the cellular mediators of the humoral immune 
response that Ehrlich described. Additionally, B cells can also act as APCs for T 
lymphocytes to direct their response. 
T lymphocytes. Also known as T cells, this class of lymphocyte is the main effector 
cell of the adaptive immune system. T cells express their own antigen-specific receptor 
known as the T-cell receptor (TCR) that is composed of a TCRα chain and TCRβ chain 
(Figure 2B). Thus these T cells are often called αβ T cells. Upon recognition of a unique 
antigen through their TCR, T cells become activated and differentiate into either cytotoxic, 
helper, or regulatory T cells. Respectively, these cells can clear cells that express the antigen 
target (CD8+ cytotoxic T cells), help support the immune response (CD4+ helper T cells), or 
even suppress the response of other immune cells (CD4+ regulatory T cells). Importantly, T 
cells can only recognize their antigen when it presented in the context MHC Class I 
molecules, which are present on the surface of all cells in the body (Figure 2B). T cells do 
not secrete their antigen receptor like B cells. Instead, they engage the target cell directly 
through the TCR:MHCI interface. 
The adaptive immunity arm of the immune system is an amazing and powerful 
weapon for not only its vast array of antigen specificity, but also its capacity for 
immunological memory. The name adaptive refers to this extremely important function.  
After being exposed to a pathogen, the body “adapts” by maintaining a small population of 
lymphocytes that were specific for the pathogen so that it can more readily respond in the 
event that pathogen is encountered again. This was the principle behind the success of early 
vaccine studies done by Jenner and others.  
 
9 
 
1.1.4 T-cell differentiation and plasticity 
 T-cell development, occurs primarily in the thymus, a specialized lymphoid organ 
located behind the sternum. After development, T cells enter the blood as so-called naïve T 
cells (TN) and migrate to peripheral lymphoid organs, such as lymph nodes, where they can 
be activated by antigens. Following activation, both CD8+ and CD4+ T cells can differentiate 
into several classes of T cells that are discernable by expression of certain surface markers 
and different, specialized functions [4]. Beyond TN, the generally accepted classes of T cells 
are central memory (TCM), effector memory (TEM), and terminally-differentiated effector 
memory (TEMRA) (Figure 3). In addition to these, recent data has suggested the existence of 
T-cell subset between TN and TCM called T stem-cell memory (TSCM) with putative stem-cell 
like attributes like self-renewal and multipotency [5]. While the exact model for T-cell 
differentiation is still debated, the general consensus is that these main T-cell states fall along 
a spectrum of progressive differentiation where TN leads to TSCM, then TCM, then TEM, and 
then finally ending with TEMRA [5] (Figure 3A). As T cells progress along this continuum, 
they become more differentiated and more short-lived. For example, TCM can persist long 
term in the body until they encounter their antigen, upon which a subset can differentiate into 
TEMRA and die off shortly after executing their effector function [4].  
 The contribution of CD4+ effector T cells is key to an efficient CD8+ T-cell immune 
response, as well as programming of optimal memory T-cell subset formation. As such, they 
are often referred to as CD4+ helper T cells (TH). Within the CD4+ TEM subset, there are 
several well-defined TH subsets: TH1, TH2, TH17, and follicular helper T cells (TFH) (Figure 
3B) [1, 6]. The differentiation of naïve CD4+ T cells into each of these subsets is mainly 
governed by specific cytokines (immune-stimulating proteins secreted by immune cells) in 
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the local environment after activation. TH1 are mainly involved in augmenting the CD8+ T-
cell immune response against intracellular pathogens, and have been known to possess 
cytotoxic effector function as well [7, 8]. TH2 coordinate the immune response against 
parasites while TH17 participate in clearance of extracellular bacteria and fungi. TFH a unique 
subset of helper T-cell that helps recruit B cells to peripheral lymphoid tissues (e.g. lymph 
nodes) as well as help regulate their response. In addition to these CD4+ effector T cell 
subsets, there is another important subset called regulatory T cells (Tregs) that modulate and 
suppress the response of CD8+ and CD4+ effector T cells [9]. While Tregs can develop 
naturally in the thymus, they can also be induced in the periphery (iTreg) by exposure to 
certain cytokines, similar to the other CD4 subsets.  
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Figure 3. Differentiation and plasticity of T cells. 
(A) After a naïve T-cell gets activated by an antigen presenting cell like a dendritic cell, it 
starts to proliferate and follow a progressive differentiation trajectory involving the different 
T-cell states. This trajectory can pause at the TSCM or TCM stage, but it eventually ends with 
the short-lived terminally differentiated effector cell (TEMRA). (B) CD4+ Helper T cells can 
differentiate (solid arrows) into several different classes initially depending on the signals 
received but also maintain the flexibility to repolarize (dashed arrows) to another state if the 
signals in the local environment change. 
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 It is important to note that TEM are not necessarily locked-in to the effector lineage 
they initially occupy. There is flexibility in the programming of their phenotype, which is a 
concept known as T-cell plasticity [4, 10]. Depending on changes in the T cells’ local 
environment, TEM can transition to a different phenotypic state. Evidence has been presented 
for this regarding the ability of the various CD4+ TH subsets to be repolarized to a different 
state based on the cytokine signals they receive [10].  For example, it is well-known that 
TH17 cells can be reprogrammed into TH1 cells with the right cytokine signals [11].  The idea 
of T-cell states being affected by their environment has taken on particular importance in 
regard to understanding CD8+ TEM function in the context of tumors. The data strongly 
suggest that functional CD8+ TEM that have infiltrated tumors follow a trajectory that 
eventually ends at a state of dysfunction that is driven by cues from the tumor and its 
microenvironment [12].  
The phenotypic and functional changes that mark T-cell differentiation and state 
changes are mediated by a cascade of alterations in gene expression. These transcriptional 
changes are governed by expression of key transcription factors that act as master regulators 
of each T cell state, either independently or in a graded manner [5-7]. The expression of 
transcription factors associated with TN cells (e.g. TCF7, LEF1, KLF2) is progressively lost 
as cells transition through the different differentiation states (i.e. TSCM to TCM and TEM). In 
their place, transcription factors associated with effector cell function are upregulated (e.g. 
EOMES, TBET, BLIMP-1). In fact, for CD8+ T-cell differentiation, the interplay between 
EOMES and TBET are key to determining the properties of T cell populations within the 
TEM subset [13]. Similarly, the different CD4+ TEM helper T-cell subsets are controlled by 
well-defined transcription factors. The TH1, TH2, TH17, TFH, and iTreg phenotypes are 
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regulated by expression of TBET, GATA3, RORγC, BCL-6, and FOXP3 respectively [6, 7]. 
Expression of these transcription factors changes accordingly during conversion of one TH 
subset to another.  Ultimately, understanding mediators of these different T-cell states, as 
well as the relationship between the different states, is key to harnessing the immune 
system’s potential.  
 1.1.5 Initiation of an adaptive immune response 
With the major players of the immune system laid out, it will be important to 
delineate the general cascade of events that comprises an immune response as they will be 
relevant later. Furthermore, while all the cells discussed in the previous section play an 
important role in an immune response, the role of cytotoxic CD8+ T cells is germane to the 
core of this dissertation, and so the events discussed in this section will focus specifically on 
their function (Figure 4). 
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In step (1) of the cycle, cancer antigens are released due to oncogenesis. These are eventually 
taken up by dendritic cells in step (2). Dendritic cells traffic to the lymph node in step (3) in 
order to present the antigen to T cells, which activates them. Upon activation, T cells leave 
the lymph node and traffic to the tumor site (4) and infiltrate it (5). Up recognition of its 
cognate antigen (6) that is bound to MHCI and expressed on the surface of the tumor, the T 
cell kills the target cell (7).  
 
 
In this context, an adaptive immune response involving T cells is initiated when they 
encounter antigens for which their TCR is specific [1]. This encounter occurs in the context 
of DCs displaying the antigen on their surface while bound to an MHC Class I molecule 
(MHCI). DCs accomplish this through a process called cross-presentation. As mentioned in 
section 1.1.2, DCs regularly uptake pathogens or molecular components from the 
environment which are then degraded intracellularly. The proteins are broken down into 
small fragments called peptides, which must be 9-12 amino acids in length for CD8+ T cells 
to recognize. These peptides are then loaded onto MHCI receptors inside intracellular 
vesicles in DCs. The peptide:MHCI complexes then traffic to the surface of the DC where 
they are displayed for T cells to interact with. The antigens that CD8+ T cells recognize via 
DC presentation are the peptides that have gone through this antigen processing pathway.  
DCs usually encounter antigens at the site of pathogenic inflammation (e.g. 
infection). While there, inflammatory signals in the milieu also activate the DCs which cause 
them to express co-stimulatory surface molecules and secrete stimulatory cytokines.  After 
activation, DCs will migrate to nearby lymph nodes, which are specialized immune organs 
that contain high densities of innate and adaptive immune cells in close proximity, in order to 
present it to a T cell with a TCR specific for that antigen. Concomitant co-stimulation of a T 
cell after activation of its TCR is also required in order to sustain the T cell activation and 
Figure 4. Initiation of an adaptive immune response against tumor. 
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proliferation. These co-stimulatory signals are provided by the activated DC expressing the 
aforementioned cytokines and cell-surface molecules. After activation, T cells will clonally 
expand, leave the lymph node as effector cells and travel to the tissue site where they will act 
to clear the threat. CD8+ T cells are able to recognize their target cells because they will also 
be displaying the antigen, bound to MHCI, on their surface. This migration is helped by 
inflammatory and chemotactic signals produced at the site of inflammation and that diffuse 
into gradients that direct immune cells. The antigen-specific population of T cells will 
contract once the target is cleared, leaving behind a small percentage of these cells that have 
differentiated into long-lived memory cells. These memory cells persist, either in the 
peripheral blood or at the tissue site, and serve as a line of rapid response in the event the 
antigen is encountered again. 
Following this general set of events, T cells are involved in the immunological 
clearance of many foreign pathogens that replicate inside the body’s cells like bacteria, 
viruses, and some parasites. After inflammatory signals produced by the pathogenic invasion 
draw T cells to the area, the T cells are able to recognize the infected cells because they 
display antigens derived from the pathogens on their surface in association with MHCI. 
These antigens are recognized as non-self and trigger the T cells’ cytotoxic function. The 
recognition of non-self by T cells goes beyond pathogens or microorganisms to include a 
multifaceted disease that is derived from normal cells in the body: Cancer. Indeed, it has 
been well established that abnormally expressed proteins in cancer are a major source of 
immunogenic antigens [14, 15]. With cancer being major health problem worldwide and the 
second leading cause of death in the United States, cancer therapy has also been a major 
focus of research for decades [16]. In recent years, particularly attention has been given to 
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understanding the immune system’s role in controlling cancer and developing methods to 
harness its potential.  
1.1.6 The immune surveillance of cancer  
Cancer is characterized by the accumulation of several genetic mutations that confer 
aberrant regulation of cell proliferation and developmental pathways, leading to unchecked 
tumor growth and spread. The steps needed for malignant transformation of normal cells to 
cancer cells were famously laid out by Hanahan and Weinberg in their “Hallmarks of 
Cancer” report [17]. These were as follows: 
1. Evasion of cell death (apoptosis) 
2. Self-sufficiency in growth signals 
3. Insensitivity to anti-growth signals 
4. Aberrant vascular growth (angiogenesis) 
5. Unlimited replicative potential 
6. Tissue invasion and metastasis 
In addition to the original six hallmarks identified, one of the new hallmarks posited by a 
follow up to this report in 2011 is the ability for cancer to evade the immune system [18]. 
While not a new idea, the inclusion of this hallmark highlights the relatively recent 
widespread acceptance of the role of the immune system in cancer control.  
In 1909, it was again Paul Ehrlich who is credited with first proposal for the role of 
the immune system in controlling cancer, even though he was unable to confirm this 
experimentally [19]. Perhaps the first experimental report of stimulating an immune response 
against cancer was reported by Ludwik Gros in 1943. Gros showed that intradermal 
immunization of mice with a sarcoma tumor line was able to induce protection against 
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rechallenge in some mice [20].  In the late 1950’s, the theory of immune surveillance of 
cancer was proposed separately by Frank MacFarlane Burnet and Lewis Thomas [21, 22]. 
They hypothesized that the immune system could recognize cancer cell neoantigens and 
respond to eliminate the nascent tumors.  However, it was not until the 1990’s that the tools 
were available to truly evaluate the role of immunity in cancer. Using mice that lacked fully 
functional immune systems, Robert Schreiber and colleagues showed that these mice were 
more susceptible to tumor formation and growth [23-25]. In the years since, this finding has 
been recapitulated by several others [26]. 
As alluded to, mutations acquired by cancer cells result in the expression of antigens 
that are not natively expressed and thus elicit an immune reaction. This then raises the 
question: if the immune system is constantly surveilling the body for signs of non-self, such 
as those displayed by cancer, then how does a tumor manage to form? This question led to a 
revision of the cancer surveillance hypothesis that is now referred to as cancer 
immunoediting and encompasses three phases of tumor growth: (1) elimination, (2) 
equilibrium, and (3) escape [1].  
 
1. The elimination phase is simply the previous working theory of immunosurveillance 
where the immune system recognizes and eliminates cancer cells. 
2. The equilibrium phase involves tumor dormancy where residual tumor is kept in 
check by the immune system. It is likely during this phase that the immune system 
effectively selects populations of tumors cells that have acquired immune evasion 
mechanisms. 
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3. The final escape phase consists of these resistant tumor cells breaking through the 
control. Mechanisms for immune evasion can be due to either changes in the tumor 
cells or the tumor microenvironment (TME).  
 
The phases of cancer immunoediting illustrate the potential of the immune system to not 
only affect tumor control but shape its immunogenicity. Understanding this has launched the 
immunotherapy revolution over the past two decades by helping to inform development of 
immune-oncology strategies that can harness the power of the immune system to prevent and 
treat cancer.  
 
1.2: Cancer Immunotherapy  
 
With the role of the immune system in tumor control having been well established, 
there has been a large effort to develop immunotherapies that can exploit and augment this 
control. Targeting of CD8+ T cells has been of particular focus due their role as main 
cytotoxic effector cells of the adaptive immune system and because the presence of CD8+ 
tumor-infiltrating lymphocytes (TIL) has been correlated with better prognosis in several 
cancer types [27]. However, factors either intrinsic to the tumor or its local environment 
often develop that lead to dysfunctional tumor-immune cell interactions [18]. Tumor escape 
can be due to a single factor such as impaired antigen recognition or due to a more 
complicated web of immunosuppressive factors in the TME. An immunosuppressive TME 
can be mediated by recruitment of regulatory immune cells, lack of co-stimulatory signals 
due to expression of inhibitory receptors, or a milieu inhospitable to immune cell function 
[26]. As a result, immunotherapy development has been focused on overcoming these 
 
19 
 
barriers and several important modalities tested in clinical trials are summarized in the 
following subsections (Figure 5).  
There are several immunotherapeutic options that can affect the T-cell anti-tumor response 
and which mediate their effect at various points throughout the cycle. Immunotherapies 
mentioned in this section are highlighted in the figure.  
1.2.1 Cytokine Therapy 
Perhaps the first example of modern immunotherapy was the use of recombinant 
cytokines, which are small, often immunostimulatory molecules that are secreted by all 
immune cells.  In particular, the identification of the T cell growth factor interleukin-2 (IL-2) 
in 1976 was a major breakthrough for the field of immunotherapy [28]. In 1984, Steven 
Rosenberg demonstrated its therapeutic potential after treatment of a metastatic melanoma 
patient with systemically administered IL-2 resulted in a complete response (CR) that has 
continued for 30 years [29]. Not only was this the first example of an effective 
Figure 5. Immunotherapies that have been developed to boost cancer immunity. 
 
20 
 
immunotherapy in humans but it also hinted at the possibility of durable responses. Several 
follow up studies resulted in high-dose (HD) IL-2 being approved by the Food and Drug 
Administration (FDA) for treatment of metastatic renal cancer in 1992 (20% overall response 
rate [ORR]) and metastatic melanoma in 1998 (16% ORR) [29].  
Interferon-α (IFN-α) was another notable entry in the immunotherapy treatment of 
metastatic melanoma. IFN-α is known to induced expression of MHCI on tumor cells as well 
as to activate immune cells [1]. It was approved in 1995 by the FDA after clinical trials 
indicated IFN-α provided a significant benefit in relapse-free survival (1 year vs. 1.7 years) 
of cutaneous melanoma in the adjuvant setting [30]. Since then, a modified version with an 
improved half-life was also approved in 2011 for resected melanoma [31]. However, using 
IFN-α is highly toxic is no longer used as the standard of care due to the advent of a class of 
immunotherapy discussed in the next section. 
While IL-2 and IFN-α are the only two approved cytokine immunotherapies for 
cancer, others have been investigated such as IL-7, IL-15, and IL-21. IL-7 and IL-15 help 
promote T cell homeostasis and expansion of memory T cells while IL-21 promotes CD8+ T 
cell activation as well as proliferation [32]. Early clinical trials for agonists of all three show 
signs of activity [33-35]. Additionally, a pegylated version of IL-2 that showed improved 
safety and pharmacodynamics in patients and is being studied in combination with other 
immunotherapies [36].  
1.2.2 Immune Checkpoint Inhibitors 
Immune checkpoint inhibitor therapy, also known as checkpoint blockade 
immunotherapy (CBI), is a revolutionary class of immune-oncology drugs. When T cells 
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become activated, they not only upregulate several costimulatory receptors to help sustain 
and propagate their response, but they also begin to express inhibitory receptors to 
counterbalance the activation [37]. These inhibitory receptors are referred to as immune 
checkpoints and their natural function is to help moderate the strength and duration of a T 
cells’ activation to limit indiscriminate cytotoxicity. Tumors are able to take advantage of 
these immune checkpoints by recruiting cells to the TME that express the ligands for these 
inhibitory receptors or by upregulating these ligands themselves. Key immune checkpoint 
molecules that are targets for therapeutic inhibition are summarized below.  
CTLA-4. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) was the first 
immune checkpoint receptors targeted in the treatment of cancer patients, following a body 
of work supporting its role in negative regulation of T cells. CTLA-4 is known to be 
expressed exclusively on activated effector T cells and can mediate immune suppression 
[37]. It was first discovered in 1987, but it wasn’t until 1995 that its function as a negative 
regulator of T cell activation was discovered [38-40]. Shortly thereafter, its mechanism of 
action was first described by Jim Allison and colleagues when they showed that it works in 
direct opposition to CD28 costimulation, a major positive signal for T cells after TCR 
activation, by preferentially binding to the same ligands [41]. Allison and colleagues 
followed up with a pivotal experiment that showed an enhancement of anti-tumor immunity 
via CTLA-4 blockade with an antagonistic antibody [42]. This work led to the development 
and clinical testing of Ipilimumab, a fully humanized anti-CTLA4 antibody. After a key 
phase III trial showed Ipilimumab to be the first drug to demonstrate survival benefit in 
advanced melanoma patients, the FDA approved it for this indication in 2011 [43]. For his 
work on developing CBI, Jim Allison shared a Nobel Prize in 2018.  
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PD-1. Programmed cell death protein 1 (PD-1) is another key checkpoint molecule 
and it was the second one targeted clinically. PD-1 is known to be upregulated on activated 
effector T cells as a result of chronic antigen stimulation, particularly on T cells that have 
infiltrated the tumor tissue [44]. Tasuku Honjo and colleagues first identified PD-1 in 1992 
and demonstrated its immune regulatory function a few years later [45, 46]. Further evidence 
by several other groups demonstrated that PD-L1, the ligand for PD-1, could be upregulated 
on tumor cells and mediate immune resistance [47, 48]. Evidence of upregulation of the PD-
1/PD-L1 axis on T cells and tumor cells prompted development and testing of several anti-
PD1 and anti-PDL1 antibodies. Two anti-PD1 antibodies, Pembrolizumab and Nivolumab, 
were approved by the FDA in 2014 for the treatment of melanoma after they showed durable 
responses in patients [49, 50]. Since then anti-PD1/PD-L1 drugs have been approved for a 
variety of other cancers, including the use of Pembrolizumab for cancers with specific 
genetic mutations (Microsatellite unstable a.k.a. MSI high) regardless of the origin. Tasuku 
Honjo shared the Nobel Prize with Jim Allison in recognition for his contribution to the area 
of CBI.  
Several other immune checkpoint molecules have emerged a potential targets, such as 
TIM3, LAG3, TIGIT, VISTA. All of these receptors, except for VISTA which is expressed 
mainly on myeloid cells, are predominantly expressed on antigen-activated T cells and thus 
are prime axes for mediating immune suppression at the tumor site. As such, there are several 
clinical studies exploring their inhibition as either monotherapy or in combination with 
already approved checkpoint inhibitors [32, 37]. The successes seen with checkpoint 
inhibitors have made them the frontline option for several indications and have energized the 
immunotherapy field.  
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1.2.3 Costimulatory activation of T cells 
 On the opposite side of the coin from reinvigorating T cells through checkpoint 
inhibition is doing it by activation through costimulatory signaling pathways. The importance 
of CD28 as a costimulatory pathway to augment TCR signaling after T cell activation has 
been known since the early 1990s [51]. Other T cell costimulators have been identified as 
well that can potentially be targeted to augment antitumor immunity. Several of the key 
costimulatory receptor targets on T cells are discussed below.  
4-1BB. 4-1BB/CD137/TNFRSF9 belongs to the tumor necrosis factor receptor 
superfamily (TNFRSF), which consists of several receptors that promote T cell survival and 
proliferation. This receptor can be expressed on several types of immune cells such as T 
cells, B cells, NK Cells, and DCs [52]. Ligation of 4-1BB with its ligand, 4-1BBL, provides 
pro-survival, activation, proliferation, and effector function signals through the NFκB and 
MAPK kinase pathways [53, 54]. With regard to T cells, 4-1BB typically becomes 
upregulated on recently antigen-activated CD8+ T cells and reaches peak expression around 
24 hrs [55].  4-1BB agonists demonstrated improvement of anti-tumor activity in mouse 
models, however use of one 4-1BB agonist in the clinic resulted in severe liver toxicities [52, 
56, 57]. It was found that this hepatotoxicity was mediated by a4-1BB activating IL-27-
producing liver myeloid cells [58]. Anti-41BB in combination with other therapeutics is 
being explored in several trials [59]. 
OX40. OX40/CD134/TNFRSF4 is another member of the TNFRSF family that is 
expressed at much higher levels on CD4+ T cells than CD8+ T cells after peptide stimulation 
in humans [54]. OX40 functions similarly on CD4+ T cells as 4-1BB does for CD8+ T cells in 
that it also provides survival and proliferation signals through the same pathways [54]. Much 
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work on agonistic OX40 antibodies has been done in mouse models where both CD8+ and 
CD4+ T cells can express OX40 [60]. Targeting OX40 has induced T-cell mediated tumor 
regression in mouse models as well as promote generation of effector and memory T cells 
[60]. There is also evidence to suggest that OX40 costimulation can abrogate CD4+ Treg 
activity [61, 62]. An early clinical trial showed that treatment with an anti-OX40 was able to 
induce tumor regression in 40% of patients [63]. Patients also showed increased CD4+ as 
well as CD8+ T cells in the blood, which was accompanied by increased in vitro anti-tumor 
response [63]. Anti-OX40 in combination with other therapeutics is being explored in several 
trials [59].  
ICOS. Inducible T-cell costimulatory (ICOS)/CD278 is a member of the same family 
of costimulatory receptors as CD28 and is expressed mainly on activated CD4+ T cells. Data 
suggests that ICOS stimulation may have indirect effects on anti-tumor response as it did not 
induce a strong response by itself in mouse models [59]. However, it does appear to provide 
benefit in the context of CBI. ICOS was found to be upregulated on CD4+ T cells after anti-
CTLA4 treatment, and subsequent ICOS simulation increased the cytotoxic T cell response 
[64]. Upregulation of ICOS after CTLA-4 blockade was also found in patients, suggesting 
stimulation of this pathway may enhance CBI efficacy in future trials [65]. Agonistic ICOS 
antibodies have only recently become available for clinical testing. 
GITR. Glucocorticoid-induced TNFR-related protein (GITR)/CD357/TNFRSF18 is a 
third member of the TNFR family. It is found on low levels of CD4 and CD8 T cells and is 
upregulated after TCR activation [66]. However, it is constitutively expressed a high levels 
on regulatory CD4+ T cells [67]. Stimulation of GITR on CD8+ T cells can enhance antigen-
specific CD8+ T-cell response, which is probably mediated in part by inducing resistance to 
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Treg suppression [68, 69].  Data from mouse models showed that GITR agonism either alone 
or in combination with anti-PD1 or anti-CTLA4 could induce tumor regression that was T 
cell dependent [70, 71]. A recent clinical trial in patients with advanced, refractory cancers 
reported that GITR agonism combined with PD-1 blockade resulted in reduced Tregs levels 
systemically and in the tumor as well as enhanced CD8+ T cell activity [72].  
1.2.4 Cancer Vaccines 
 Cancer vaccines take advantage of the first step in initiating an immune response, 
which is antigen presentation by DCs to prime T cell responses The goal of vaccination is to 
use DCs loaded with either tumor cells or tumor-associated antigens (TAA), to augment the 
immune response against cancer. The use of an adjuvant is required to help stimulate the 
immune system to respond to the tumor antigens, as is the case with traditional vaccines 
against microbial agents.  
There are currently two FDA approved cancer vaccines that use tumor antigens. The 
first is Sipuleucel-T, which is an autologous DC vaccine used to treat castrate-resistant 
prostate cancer [73]. The vaccine works by incubating the patients’ DCs with a nearly 
universally expressed prostate cancer TAA as well as the DC stimulating cytokine 
granulocyte-macrophage colony-stimulating factor (GM-CSF), and then reinfusing them into 
the patients. This treatment only improved survival by 4 months [73]. The second is T-VEC, 
which takes advantage of stimulating the immune system with tumor antigens in round-about 
way. T-VEC uses an oncolytic herpes virus that is modified to be less virulent as well as to 
express GM-CSF. The vaccine is designed to elicit a systemic anti-tumor response by 
infecting cancer cells and causing them to burst, spreading antigens. It was approved in 2015 
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for late stage melanoma and produced a 26.4% ORR vs. 5.7% ORR for patients who only 
received subcutaneous GM-CSF [74]. 
Beyond these, there are several cancer vaccines in development that use either 
modified tumor cells and/or TAAs. In particular, many TAAs have now been identified and 
cancer vaccines could be a prime way to take advantage of directing the immune system 
against targets specific to tumor cells. A phase III trial in stage III and IV melanoma using a 
gp100 peptide vaccine plus IL-2 showed only a small improvement in progression free 
survival compared to IL-2 alone. (2.2 months vs. 1.2 months) [75]. A TAA-based vaccine in 
Her2+ breast cancer, where patients were immunized with a Her2 peptide plus GM-CSF, 
showed modest clinical activity in an early phase clinical trial (89.7% vs. 80.2% disease-free 
survival) [76]. Another clinical trial by Elizabeth Jaffee and colleagues utilized GM-CSF 
secreting allogeneic pancreatic tumor cells in combination with live-attenuated Lysteria 
expressing mesothelin, which is a pancreatic cancer TAA [77]. Unfortunately, the 
combination did not improve survival over chemotherapy.  
In addition to targeting shared TAAs, there are also efforts to treat patients with so 
called personalized cancer vaccines. These studies identify neoantigens (i.e. new antigens 
expressed only by cancer cells typically due to a mutation) that are not only highly specific to 
the cancer but also to each individual patient, too. Several studies were done in melanoma 
patients, demonstrating induction of neoantigen specific T cells as well as clinical benefit 
[78-80]. Furthermore, a more recent neoantigen vaccine trial showed similar T cell responses 
in glioblastoma [81]. Among others, there have also been efforts at MD Anderson Cancer 
Center to treat metastatic colorectal cancer and pancreatic cancer patients with personalized 
peptide cancer vaccines. Indeed, within the past few years, several other trials involving 
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peptide-based anticancer vaccines were terminated early due to lack of efficacy or lack of 
scientific rationale to continue [82]. While vaccination can induce antigen-specific T cells, 
evidence suggests that combination with other immunomodulatory agents (like the ones 
mentioned in the previous subsections) will be needed to induce tumor clearance. As such, 
there are several current studies that are addressing this need by combining cancer vaccines 
with blockade of PD-1, CTLA4, TIM3, LAG3 or costimulation of 4-1BB, OX40, GITR, 
CD27 [83, 84].  
 
1.3: Cellular Immunotherapy for Cancer  
 
 The presence of T cells in the tumor, particularly CD8+ T cells, has been correlated 
with improved survival in a myriad of cancer types which is suggestive of their anti-tumor 
potential [85-92]. From current general immunology knowledge of T cell function, it is likely 
that at least some of the T cells in the tumor have migrated and arrested there in response to 
the tumor [1, 93]. As already stated, the idea that tumors can persist despite the presence 
tumor-infiltrating lymphocytes (TIL) led to the identification of several mechanism of tumor 
immune evasion which have been discussed. Futhermore, the identification of IL-2 as a 
soluble T-cell growth factor allowed ex vivo propagation of T cells in order to study their 
function. Taken all together, this knowledge provided the rationale for exploring cellular 
immunotherapies with adoptively transferred T cells. In general, adoptive cell therapy (ACT) 
uses the idea that by removing TIL from a restrictive and immunosuppressive environment, 
they can be reinvigorated and expanded to prognostically favorable numbers. Transfer of 
these cells back to the patient as a large boost of anti-tumor immunity can result in 
eradication of established tumors and long-term progression-free survival [94, 95]. T-cell 
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therapy was pioneered by Steven Rosenberg using TIL based ACT for the treatment of 
melanoma in the 1980s. Since then, attempts to build on the success of TIL ACT in 
melanoma have included genetically engineering lymphocytes (including NK cells) to 
express chimeric-antigen receptors (CAR-T), antigen-specific TCRs, or receptors to improve 
their functionality at the tumor site. Since ACT is central to the work in this dissertation, 
these strategies will be discussed at length in this section (Figure 6). 
 
Figure 6. The three main forms of adoptive cell therapy. 
Adoptive cell therapy is a form of immunotherapy that augments the patient’s anti-tumor 
response by transferring large numbers of ex vivo expanded T cells. The first (1) approach is 
engineering T cells, typically taken from the blood, using viral vectors to express either a 
chimeric antigen receptor (CAR) or antigen-specific T-cell receptor. The second (2) method 
relies on the isolation and expansion of low-frequency antigen-reactive T cells from the 
blood. The third (3) therapy grows tumor-infiltrating lymphocytes ex vivo from patients’ 
biopsies or resected tumors.  
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1.3.1 Adoptive cell therapy with tumor-infiltrating lymphocytes  
 The basic principle of TIL ACT involves the patient’s tumor being resected, cut into 
small fragments, and cultured with IL-2 to stimulate expansive TIL growth ex vivo [96]. 
Once the TIL reach sufficient number, they undergo a second large expansion phase to be 
able to reinfuse billions of cells into the patient to effect tumor clearance [96]. The first 
example of this was demonstrated by Rosenberg and colleagues in a murine model of 
lymphoma, and its effect was further enhanced with systemic IL-2 administration following 
TIL infusion [97, 98]. Observation that human anti-tumor TIL could be consistently isolated 
from melanoma led to the first demonstration that ACT with autologous TIL could mediate 
tumor regression in melanoma patients [99-101]. Despite these early promising results, the 
duration of responses (DOR) was often short-lived (2-13 months) and infused TIL rarely 
persisted for more than a few days in the patient [102].  
As such, Rosenberg and colleagues at the NCI worked to improve the early TIL 
generation and administration process. A major development was the observation that 
lymphodepletion of patients prior to adoptive TIL transfer improved response as well as 
engraftment of the transferred cells. Mechanistically, the superior TIL persistence afforded 
by lymphodepletion is believed to be mediated by the removal of endogenous homeostatic 
cytokine sinks by the lymphodepleting regimen [103, 104]. Furthermore, a “young TIL” 
culture protocol was established that reduced culture time, and increased patient eligibility 
was achieved by making the assumption that all TIL cultures contain anti-tumor activity and 
removing the TIL reactivity testing step, thus making TIL ACT more accessible. While the 
young TIL method did decrease the time of culture and had attributes associated with better 
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persistence, it resulted in response rates below what was reported for the traditional method 
(35% vs. 49% ORR) [94, 105, 106].  
With the success of TIL ACT in melanoma established at by Rosenberg and 
colleagues, other medical centers have sponsored clinical TIL ACT trials for melanoma and 
there have been 13 studies to date that followed the general protocol laid out by the National 
Cancer Institute [107]. Since most (8/13) trials use HD IL-2 after TIL infusion, which is the 
model followed at MD Anderson Cancer Center in particular, only the results of these trials 
will be discussed as they are the most relevant.  A meta-analysis of these trials found that the 
ORR at the different centers were consistent with each other, indicating the reproducibility of 
TIL ACT [107]. The overall ORR was 43%, which included 15% CR and 28% partial 
responses (PR). From the available data, the overall median DOR was not reached for CRs 
after 48 months and 11.5 months for PRs.  Furthermore, a TIL dose consisting of ≥50x109 
cells and a more CD8+ TIL rich product were both correlated with better response [107-109].  
Given the potential, there have also been attempts to push TIL ACT beyond 
melanoma, particularly for cancer types in need of improved therapies and that have not yet 
responded well to CBI. Several recent preclinical and clinical studies have been published in 
ovarian cancer, various gastrointestinal (GI) epithelial cancers, colorectal cancer, HPV+ 
cervical cancer, breast cancer, pancreatic cancer, and non-small cell lung cancer [110-120]. 
Efforts to further improve the feasibility of TIL ACT for solid tumors other than melanoma 
will be delineated in subsequent chapters. 
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1.3.2 Antigen-specific T cell therapy 
The success of TIL ACT in melanoma has provided the impetus to improve upon the 
therapy by improving the antigen-specificity, either through selection of antigen-specific T 
cells or genetic engineering of T cells to express certain antigen-specific TCRs. The natural 
starting place is to identify the specific T cells and their cognate antigens which mediate the 
immune responses seen. TAAs typically fall under the category of either shared non-mutated 
antigens, such as cancer testis antigens or differentiation antigens that are overexpressed in 
cancers, or private neoantigens deriving from tumor mutations that are usually specific to the 
individual’s cancer [121]. Early studies in melanoma identified two differentiation antigens, 
MART-1 and gp100, that were well recognized by melanoma TIL [122, 123]. A clinical 
study using T cells that were virally transduced with high-affinity TCRs for these antigens 
showed cancer regression in several patients [124]. TCR-engineered T cell therapy has also 
shown some success in a clinical trial for patients with melanoma (45% ORR; 5/11 patients) 
and synovial sarcoma (66% ORR; 4/6 patients) with T cells targeting the cancer testes 
antigen NY-ESO-1 [125]. However, targeting shared antigens can have sometimes serious 
on-target off-tumor effects as they can be expressed in normal tissues also [125-127].  
These potential issues have raised interest in targeting tumor-specific mutated 
antigens and the emergence of next-generation sequencing has made this possible [128, 129]. 
Several retrospective studies of ACT TIL treated patients have identified neoantigen-reactive 
TIL in the infusion products for melanoma, various epithelial gastrointestinal tumors, and 
breast cancer [112, 114, 130].  It is unclear how much these TIL contributed to tumor 
regression since they were not pure populations of antigen reactive cells, but it is likely they 
played some part given the evidence that increased mutation load correlates with increased 
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survival in general as well as better response to CBI [131-134]. Further studies have also 
identified TIL from patients that recognize antigens from driver mutations like TP53 and 
KRAS in colorectal cancer, ovarian cancer, and pancreatic cancer [115, 135-137]. 
Interestingly, Eric Tran and colleagues at the NCI identified TIL from two different 
colorectal cancer patients that recognized KRAS neoeptiopes restricted to the same MHCI 
allele, hinting at the possibility of developing TCR-engineered T-cells targeting common 
driver mutations across multiple tumor types [115].   
In addition to finding antigen-specific T cells or TCRs at the tumor site, antigen-
reactive endogenous T cells (ETCs) can also be found circulating in the blood. These ETCs 
can be isolated from peripheral blood and expanded ex vivo for ACT in a method called ETC 
Therapy [138]. T cells specific for the melanoma associated antigens MART1, tyrosinase and 
gp100 were observed in the peripheral blood of melanoma patients [139-141]. Technical 
hurdles face ETC given that circulating antigen-specific T cells are often <0.1% of the 
peripheral population, but techniques such as cell sorting with tetramers have allowed this 
therapy to be translated into the clinic. To date, several ETC Therapy trials have been 
conducted in melanoma patients [138]. While many of the studies demonstrated clinical 
benefit (i.e. stable disease) and some patients experienced durable complete responses, the 
ORR generally remained less than 25%. The only exception is a study by Khammari et al. 
that reported a 43% ORR, which is comparable to the response rates reported for TIL ACT 
[142]. While challenges still remain to improve ETC Therapy, it could eventually be 
transposed to other cancer types as evidenced by a recent report that identified circulating 
neoantigen reactive T cells in gastrointestinal cancer patients [143].  
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1.3.3 Chimeric-antigen receptor T cell therapy 
 In the effort to improve the antigen-specificity and function of adoptive transferred T 
cells, genetically engineering them to express chimeric-antigen receptors (CARs) is the next 
logical step. Endogenous CD8+ T cell activation by its cognate antigen relies on recognizing 
it while bound to MHCI and also requires costimulation to help sustain the activation [1]. 
However, MHCI expression loss and lack of proper costimulation are two well-known 
mechanism of immune evasion [1]. Additionally, TCR-affinity for shared TAAs can 
sometimes be weak. As such, CAR-T cells, have been proposed as a way to overcome these 
potential issues. CARs were pioneered in the late 1980s and essentially use a receptor that is 
composed of an extracellular antigen-binding domain of an antibody that is linked to 
intracellular signaling chains. These are typically the CD3-ζ chain from endongenous TCRs 
stacked on top of costimulatory domains (e.g. CD28, 4-1BB, OX40) to provide complete 
activation [144-146]. CARs can be easily transduced into patient T cells using viral vectors. 
In this way, CAR-T can easily provide non-MHC–restricted recognition of cell-surface 
TAAs.  
 Unfortunately, the same pitfalls with using endogenous TCRs specific for non-
mutated public antigens can also apply to CAR-T [147]. This makes targeting these kinds of 
cancer antigens that are also normally expressed on non-essential tissues an important 
consideration to avoid serious toxicity. In fact, it is in this realm that CAR-T has seen 
overwhelming success. Targeting B cell malignancies like acute lymphoblastic leukemia 
with CD19-targeted CAR-T has produced complete response rates ranging from 70% to 91% 
in children and adults [148]. In 2017, this led to a CD19-directed CAR-T (Kymriah) to being 
not only the first cellular therapy approved by the FDA, but also the first treatment to include 
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gene therapy. There are currently several more trials ongoing for other hematological 
malignances using CAR-T against new antigen targets [148]. While blood cancers have 
enjoyed remarkable response rates with CAR-T, the efficacy in solid tumors is still unclear. 
So far, the only example of strong regression in solid tumors is in glioblastoma using CAR-T 
targeting Interleukin-13 receptor alpha 2 [149].  Unfortunately, this patient recurred after 
about 8 months. Several CAR-T trials in solid tumors are currently ongoing for prostate 
cancer, mesothelioma, pancreatic cancer, glioma, glioblastoma, and sarcoma [148]. Several 
CAR-T trials in solid tumors are currently ongoing for prostate cancer, mesothelioma, 
pancreatic cancer, glioma, glioblastoma, and sarcoma [148].  
 CAR-T also suffers toxicities associated with cytokine release syndrome and 
neurotoxicites, which are probably a result of patients being infused with a large amount of 
activated T cells [147]. Finally, while there is also the issue of antigen loss being a 
mechanism of immune escape since CAR-T only target one antigen, there are some 
preclinical studies addressing this issue by using CAR-T multiple specificities [150]. 
 
1.4: Improvement of TIL-based Adoptive Cell Therapy 
 
 While TIL ACT has provided the best results for solid tumors in terms of cellular 
therapy, there are still opportunities for improvement. The numerous preclinical and clinical 
studies over the past 30 years have revealed several factors important the efficacy of TIL 
ACT: (1) Generation of a clinically relevant number of TIL that are (2) enriched for antigen-
specific TIL and (3) that display phenotypic characteristics that confer improved 
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functionality and durable persistence. Previous work from our group and others has focused 
on addressing these points so as to increase the scope and efficacy of TIL ACT. 
1.4.1 Adding 4-1BB costimulation  
 Several TIL ACT trials for melanoma patients demonstrated that a high number of 
total TIL infused, and in particular a higher amount of CD8+ TIL, is correlated with objective 
response [108, 151, 152]. However, several studies have found inconsistent generation of a 
large amount of CD8+ TIL from tumor fragments with high-dose IL-2 (6000 U/mL).  
Reported success rates for general TIL growth range from 31-94%, although no consistent 
cut-off number was used between studies [109, 153-155]. With regard to the TIL ACT 
experience and MD Anderson Cancer Center, it was found that 40x106 cells were needed in 
the initial expansion to confidently move forward to the expansion phase [156]. The reported 
success rate with this cut-off was 62%. Likewise, the reported fraction of CD8+ TIL in the 
initial expansion product or infusion product varied widely, although the overall average 
CD8% was >50% [108, 152, 157, 158]. Finally, the time of initial TIL expansion phase 
reported in these studies showed that it can last from 3-5 weeks. Tran et al. demonstrated that 
the longer TIL remain in culture, the more differentiated they become (based on CD27 and 
CD28 expression) and the shorter their telomeres [158]. Both of these characteristics have 
been correlated with worse clinical response, TIL persistence, and proliferation [159-161]. 
 Taken together, these identified shortcomings provided points of attack to improve 
the quality of the TIL product generated. As such, 4-1BB costimulation provides a way to 
address these points given the signaling pathway’s ability to improve the proliferation, 
survival, and effector function of CD8+ TIL [53, 162-164]. 4-1BB signaling accomplishes 
these results by activating the NF-κB and MAPK pathways, which are well-known regulators 
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of cell survival, maturation, and proliferation (Figure 7) [165-168]. Ligation of 4-1BB, either 
through interaction with trimers of its natural ligand 4-1BBL or through crosslinking with an 
agonistic antibody, recruits TNFR-associated factor (TRAF) 1, TRAF2, and TRAF3 to its 
cytoplasmic tail, which form heterotrimers themselves [169]. TRAF1 functions to sustain 
TRAF2 expression and signaling while 4-1BB signaling seems to be dependent on TRAF2 
participation [170]. TRAF2 has E3-ubiquitan ligase activity, acting as a scaffold for the 
recruitment of factors that ultimately lead to the activation of NF-κB and MAPK signaling 
[169]. Induction of 4-1BB signaling results in the secretion of IL-2 and IFN-γ, and the 
expression of the anti-apoptotic proteins Bcl-xL and Bfl-1, which protect against activation-
induced T-cell death [162, 163].  
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Figure 7. 4-1BB signaling pathway. 
When 4-1BB signaling is triggered in the T-cell, TRAFs are recruited to the cytoplasmic tail 
in order to propogate signaling via the NFκΒ and MAPK/ERK pathways that ultimately 
result in changes in gene expression geared towards pro-survival, proliferation, and effector 
functions.  
 
Previous work in the lab by Chacon et al. focused on the effects of integrating a fully-
human agonistic 4-1BB monoclonal antibody (a4-1BB mAb) from Bristol-Myers Squibb 
(Urelumab; BMS 663513) into the TIL expansion process. Addition of a4-1BB to the tumor 
fragment culture (initial expansion phase) augmented and accelerated CD8+ TIL growth 
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compared to using IL-2 only, which seemed to be helped by activation of DCs within the 
tumor tissue [171]. This also resulted in increased tumor specificity, which is likely due to 
the fact that 4-1BB costimulation targets and enriches for recently antigen-stimulated CD8+ 
TIL [53, 55, 172]. Furthermore, use of a4-1BB also protected TIL from activation-induced 
cell death (AICD), to which they were previously found to be susceptible, after the second 
large expansion phase [173]. Additionally, its use during the large expansion phase 
maintained their CD28 expression which is correlated with longer telomeres [159, 171, 174].  
 The importance of 4-1BB costimulatory signaling has been corroborated by other 
groups as well. CD28 is probably the most widely recognized costimulatory signal following 
TCR activation. As such, most classical methods of expanding T cells in vitro involve anti-
CD3/anti-CD28 microbeads. However, these beads typically preferentially expand CD4+ T 
cells instead of CD8+ T cells [175-177]. Furthermore, it has been reported that the 4-1BB 
costimulation better expands memory, antigen-specific, CD8+ T cells than compared to 
CD28 costimulation, which were mainly naïve cells [178]. Beyond improving proliferation 
and cytotoxicity, 4-1BB costimulation also has more beneficial effects on T cell metabolism 
as compared to CD28 signaling. Several studies have revealed that 4-1BB costimulation 
results in metabolic reprogramming that involves mitochondrial enlargement, increased 
mitochondrial respiratory capacity, and increased mitochondrial biogenesis [179-181]. These 
alterations may ultimately improve T cell persistence and anti-tumor activity. Finally, 4-1BB 
costimulation appears to impart lasting benefits that are mediated by epigenetic changes 
[182].  
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1.4.2 Improving TIL product with gas-permeable culture flasks 
 Ways to improve TIL growth are not just limited to growth factors provided in culture 
medium. Treating patients with ACT TIL can also be improved by the materials used and the 
simplification of manipulating the cultures. The traditional TIL growth protocols use 24-well 
tissue culture plates, various sizes of tissue-culture flasks, and gas-permeable bags [157]. Use 
of novel gas-permeable flasks (GREX), which have a membrane on the bottom upon which 
cells sit, have improved TIL expansion and simplified the logistics, thus making the process 
more accessible [183, 184]. In addition to this important but oft over looked component, the 
GREX flasks were also found to be beneficial for the TIL function and phenotype [185]. Due 
to the position of the TIL on top of the gas-permeable membrane, the cells can take 
advantage of the increased oxygen exchange. This resulted in rescue of TIL growth for 
cultures that did not expand in the traditional flasks, maintenance of clonal diversity, and 
improved mitochondrial function [185]. Furthermore, the GREX flasks also affected a 
beneficial phenotypic change on the TIL as marked by increased fraction of CD8+BTLA+ 
TIL. BTLA, or B-and-T lymphocyte attenuator, is traditionally thought of as a negative 
regulator on T cell function [186, 187]. However, a higher percentage of BTLA expressing 
CD8+ TIL in the infusion product was correlated with persistence and response in TIL treated 
patients [108]. Further work by Haymaker et al. and Ritthipichai et al. laid out respectively a 
possible explanation for this by showing that, compared to CD8+ TIL lacking BTLA 
expression, BTLA+CD8+ TIL are less differentiated (“younger”) and able to serially kill 
cancer cells [188, 189]. 
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1.4.3 Genetic engineering of TIL to improve function 
 As our understanding of biological processes continues to improve, it’s likely that the 
next generation of cellular therapeutics will involve genetic engineering. So far this is best 
exemplified by the ground-breaking FDA approval of a CD19 CAR-T, not only the first 
cellular cancer immunotherapy approved, but the first to involve genetic engineering. 
Biological manipulation like this is not restricted to expression of chimeric-antigen receptors 
or antigen-specific TCRs, but can also produce so called “armored” T cells that will be able 
to resist or even exploit immunosuppressive signals as well as provide their own cytokine 
stimulation. 
 Receiving supportive stimulation from cytokines is an important aspect of a sustained 
immune response, with IL-2 being one of the most well-known T cell growth factors. Early 
preclinical studies by Rosenberg and colleagues established that transduction of human T 
cells with the IL-2 gene allowed prolonged persistence in vitro without exogenous IL-2 and 
could produce their own IL-2 upon TCR activation [190, 191]. Based on this, TIL ACT with 
IL-2 transduced TIL could be beneficial due to improved persistence in vivo [192]. Other 
promising cytokines have been explored as well, like IL-12 and IL-15, due to their effector T 
cell proliferative and protective abilities [193-196]. Being able to provide local 
administration of lymphoproliferative cytokines could help overcome suppression in the 
TME as well as avoid toxicities associated with systemic cytokine administration [197, 198]. 
 There have also been efforts to improve T cell anti-tumor activity via expression of 
non-endogenous receptors. In melanoma, ACT with TIL expressing the CXCR2 chemokine 
receptor could allow for better trafficking to tumors due to their expression of the CXCR2-
ligands CXCL1 and CXCL8 [199, 200]. Once there, improved activity could be endowed by 
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incorporation of dominant-negative receptors (lack intracellular signaling domains) for TGF-
β or Fas, thus resisting immunosuppression of apoptosis respectively [201-203]. A method to 
expand genetically engineered TIL for ACT has been established and will facilitate future 
studies of this type [204].  
 
1.5: Main Theoretical Questions 
 
 The success of CBI has reinvigorated the cancer therapy field, particularly for 
advanced melanoma which has double the survival rates compared to 20 years ago [16, 205]. 
Prompted by this, the race to expand treatment to other cancer types is in full swing. Several 
tumor types have received great benefit (e.g. NSCLC, RCC, MSI-Hi), but they often belong 
to the same category of being highly immunogenic and/or being immune-inflamed [206-
208]. Unfortunately, there are many more solid tumor types (e.g. pancreatic, ovarian, breast, 
MSS colorectal, prostate cancer) that fall on the other end of the spectrum and in which CBI 
has been ineffective so far. Given the heterogeneity of cancers, the immune contexture of 
some cancer may not be conducive to CBI and instead that might benefit from 
immunotherapies that approach the issue from another angle. Despite the lack of efficacy of 
immunotherapy so far, there is still evidence for the role of TIL in control of these tumors 
[27]. Given this fact coupled with the success of TIL ACT, which can take advantage of 
antigen-specific TIL by expanding them ex vivo, I sought to assess the feasibility of this 
therapy in other solid tumors that still have an unmet need.  
One such tumor type is pancreatic cancer. Several immunotherapy trials, CBI or 
otherwise, have failed to provide improved clinical benefit compared to 
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surgery/chemotherapy, which remain the standard of care [77, 209-213]. As such, the 5-year 
survival rate remains the lowest of any cancer type at <10% [16]. In contrast to melanoma, 
pancreatic cancer TME is characterized by an extensive stromal compartment composed of 
immunosuppressive immune cells and a fibrotic extracellular matrix [214, 215]. In spite of 
this seemingly restrictive immune TME, the presence of TIL is correlated with increased 
survival [85, 216].  Therefore, I investigated transposing TIL ACT to pancreatic cancer with 
the following hypothesis and specific aims to guide me: 
Hypothesis: Tumor-specific TIL exist in solid tumors beyond melanoma and their potential 
for tumor clearance can be harnessed through TIL-based Adoptive Cell Therapy. 
I. Specific Aim 1: Determine the immune and molecular landscape of TIL in pancreatic 
cancer (PDAC) and ovarian cancer (OvCA)  
II. Specific Aim 2: Elucidate requirements for TIL expansion in PDAC and OvCa, and 
determine phenotypic attributes of the expanded TIL  
III. Specific Aim 3: Interrogate the presence of tumor-reactive TIL in TIL generated 
from tumors generally unresponsive to current immune checkpoint blockade therapy 
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Chapter 2: Materials and Methods 
 
Patient selection 
Pancreatic Cancer Samples. After obtaining written informed consent, 61 patients 
with primary or metastatic pancreatic ductal adenocarcinoma underwent surgical resection. 
Patients are referred to by their de-identified “MP” number. Tissue from surgical resections 
was used to expand TIL under protocols (PA15-0176, LAB00-396, PA15-0014 for PDAC 
samples and LAB06-0755 for melanoma samples) approved by the Institutional Review 
Board of The University of Texas MD Anderson Cancer Center.   
Ovarian Cancer Samples. Patients with primary or metastatic high-grade serous 
ovarian carcinoma underwent surgical resection (n=98, 84 evaluable for flow cytometry). In 
47 patients, platinum-based chemotherapy and/or chemoradiation was administered. Patients 
are referred to by their de-identified number.  Informed consent was obtained from all 
individual participants included in the study for their specimens and data to be used in 
research and for publication. 
Ethical approval and tissue from surgical resections used to expand TIL were both obtained 
under protocol (PA16-0912 and LAB02-188) approved by the Institutional Review Board of 
The University of Texas MD Anderson Cancer Center. 
 
Reagents and cell lines 
A fully human and purified IgG4 monoclonal antibody (mAb) against human 
CD137/4-1BB, Urelumab (663513), was kindly provided by Bristol-Myers Squib (BMS). 
Human recombinant interleukin-2 (IL-2) (ProleukinTM) was generously provided by 
Prometheus Therapeutics & Diagnostics. MHC class I blocking antibody (clone W6/32) and 
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isotype control (mouse IgG2a, clone eBM2a) were purchased from Invitrogen and 
eBioscience, respectively. Autologous pancreatic tumor targets were found to match the 
patients using STR DNA fingerprinting performed at MDACC and the tumoroid was 
confirmed mycoplasma-free. CAPAN-1 and SKOV3 cell lines were purchased from ATCC. 
COV318 and COV362 were purchased from Sigma-Aldrich (now Millipore-Sigma, St. 
Louis, MO). All cell lines were HLA-typed, STR fingerprinted, and confirmed mycoplasma-
free at MDACC. 
 
Isolation and expansion of TIL from human solid tumors  
The tumor samples were cut into 1-3 mm2 fragments and placed in TIL culture media 
[TIL-CM: RPMI-1640 with GlutaMax (Gibco/Invitrogen), 1× Pen–Strep (Gibco/Invitrogen), 
50 μmol/L 2-mercaptoethanol (Gibco/Invitrogen), 20 μg/mL Gentamicin (Gibco/Invitrogen), 
and 1 mmol/L sodium pyruvate (Gibco/Invitrogen] with 6000 IU/ml IL-2 in 24-well plates 
for up to 5 weeks, as previously described [108, 217]. The same method was applied for the 
metastatic melanoma samples. For the 4-1BB mAb (a41BB) condition, both 6000 IU/ml IL-2 
and 10 ug/ml 4-1BB mAb were added in the culture plates on day 0 and day 4 or 5. TIL were 
expanded for up to 35 days prior to performing the described assays or the rapid expansion 
protocol (REP). For the IL-2+OKT3+a41BB condition, five tumor fragments were put in a 
G-Rex 10 flask (Wilson Wolf Manufacturing, New Brighton, MN) in 20 mL TIL-CM with 
6000 IU/mL IL-2, 10 ug/mL 4-1BB mAb, and 30 ng/mL anti-CD3 (OKT3) as previous 
described [218]. Four to five days after culture initiation, 20 mL of additional TIL-CM with 
6000 IU/mL IL-2 was added. Half-media changes were done every 3-4 days with fresh TIL-
CM containing 6000 IU/mL IL-2 for up to 35 days or until the cells formed a thick layer 
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completely covering the bottom of the flask. The cell suspensions were collected and 
cryopreserved for later testing.  
 
Cell Sorting and Rapid Expansion of CD8+ OvCa TIL 
To control for reactivity of CD8+ TIL, bulk TIL products were stained with CD3 
FITC, CD8 APC-H7, and SYTOX Blue Dead Cell Stain in order to isolate the CD8+ T cells 
using a BD FACSAria IIIu in the MD Anderson Cancer Center (MDACC) Flow Cytometry 
and Cellular Imaging Core Facility. Then, to provide greater cell numbers for functional 
assays, the sorted CD8+ TIL underwent the rapid expansion protocol in G-Rex10 flasks, 
which was previously described by Forget et al. and then viably-frozen [217]. Briefly, the 
REP was performed in the G-Rex 10 device (Wilson Wolf Manufacturing) following a 
scaled-down version of the previously described protocol [217]. Briefly, TIL were put in 
culture with pooled allogeneic irradiated PBMC feeder cells at a ratio of 1 TIL to 200 feeders 
in combination with 6000 IU/ml IL-2 and 30 ng/mL of anti-CD3 (OKT3 clone) on day 0 of 
the REP. The REP process lasted for 14 days, with REP-CM (half TIL-CM and half AIM-V 
(Invitrogen)) used for the first 7 days and only AIM-V for the last 7 days of expansion. The 
cells were collected and cryopreserved for later assays.  
 
Immunohistochemistry (IHC) 
Four-micrometer-thick serial sections were obtained from representative formalin-
fixed, paraffin-embedded (FFPE) blocks for IHC, as well as hematoxylin and eosin (H&E) 
staining. H&E slides were examined by a pathologist to confirm the presence of tumor. IHC 
was performed using a Leica Bond Max automated staining system (Leica Microsystems) 
with antibodies against CD3 (dilution 1:100; Dako). The expression of the marker was 
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detected using a Leica Bond Polymer Refine Detection kit (Leica Microsystems) 
with diaminobenzidine reaction to detect antibody labeling. Counterstaining was done using 
hematoxylin. Human tonsil FFPE tissues with and without CD3 primary antibody were used 
as positive and negative controls, respectively. For quantification of CD3 expression, the 
slides were digitally scanned at 200 magnification using the Aperio AT2 scanner (Leica 
Microsystems). The images were visualized using the ImageScope software (Leica 
Microsystems) and analyzed using the Aperio Image Toolbox (Leica Microsystems). Five 
regions of interests were randomly selected within the tumor area of each slide. The 
number of CD3 positive cells per mm2 (cell density) was evaluated, and the final score was 
expressed as the average density of the five areas.  
 
Flow Cytometric Analysis of TIL 
Fresh tumor samples were manually disaggregated between frosted-glass slides to 
obtain a single-cell suspension for analysis. Both the disaggregated tissue samples and 
expanded TIL were blocked in FACS Wash Buffer (Dulbecco’s Phosphate Buffered Saline 
1X with 1% Bovine Serum Albumin) supplemented with 5% goat serum (Sigma-Aldrich) for 
10 min at room temperature. Cell suspensions were then stained in FACS Wash Buffer for 30 
min using fluorochrome-conjugated monoclonal antibodies for CD3, CD4, CD8, CD16, 
CD56, CD57, Granzyme B, TBET, γδ TCR, CD27, CD28, CD45, CD45RA, CD45RO, 
CCR7, CD103, CD152/CTLA4, BTLA (clone J168) (BD Bioscience), CD25, CD279/PD-1, 
KLRG1, CD278/ICOS, CD366/TIM3 (Biolegend), and CD223/LAG3, FoxP3, Ki67, 
CD357/GITR, Eomes (eBioscience/ThermoFisher). Stained cells were fixed in 1% 
paraformaldehyde solution for 20 min. Intracellular staining was performed using 
eBioscience transcription factor staining kit according to the manufacturer’s instructions. 
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Samples were acquired using the BD FACSCanto™ II or BD LSRFortessa X-20 and 
analyzed using FlowJo Software v10.2 (Tree Star). Dead cells were excluded using an 
AQUA or Yellow live/dead staining (Invitrogen).  
 
T-cell Receptor Beta Sequencing 
Genomic DNA was extracted from samples using DNeasy Blood & Tissue Kit 
(Qiagen) as per manufacturer’s instructions. TCRβ CDR3 regions were amplified from 
between 0.2–3 μg of DNA. All samples had the ImmunoSEQTM assay performed at Adaptive 
Biotechnologies, with deep sequencing for PBMC DNA and survey-level sequencing for all 
others. Data analysis was performed at MDACC. 
 
Preparation of Single-Cell RNA Sequencing Libraries for PDAC TIL 
Fresh tumor samples were disaggregated using a MediMachine (BD Biosciences) to 
create a single-cell suspension. After disaggregation, CD3+ T cells were isolated for 
sequencing via magnetic bead separation using the EasySepTM Release Human CD3 Positive 
Selection Kit (StemCell Technologies) according to the manufacturer’s instructions. For 
cultured TIL, previously cryopreserved samples were thawed, washed with PBS, and 
resuspended at 1x106 cells/mL. The single-cell RNA sequencing libraries were prepared 
according to the protocol for the 10x Genomics ChromiumTM Single-cell V(D)J Regent Kits 
using the v1 chemistry. T cells were loaded on a Chromium single-cell A chip and placed in 
a Chromium controller where they were partitioned into single-cell droplets to undergo cell 
barcoding and cDNA synthesis. After isolation of the cDNA by DynaBeads MyOne Silane 
beads, it was then PCR amplified, again purified by size-selection using SPRIselect 
(Beckman), all according to the manufacturer’s instructions. For construction of the gene 
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expression library, 50 ng of amplified cDNA was fragmented, end repaired, sized-selected 
using SPRIselect and PCR amplified again according to the manufacturer’s instructions. For 
the TCR library, 2 ul of amplified cDNA was used for enrichment of TCR transcripts via the 
Chromium Human T cell V(D)J Enrichment Kit and purified using SPRIselect, both 
following the manufacturer’s instructions.  
 
Sequencing of the TCR and gene expression libraries 
The transcriptome libraries were pooled and sequenced paired-end (26 cycles read 1, 
91 cycles read 2, 8 cycles i7) on the Illumina Novaseq to a targeted depth of 600M paired-
end reads per library. TCR libraries were pooled and sequenced on the Illumina Miseq 150bp 
paired-end to a targeted depth of 1000 reads per T-cell.  
 
Unsupervised clustering of scRNAseq data 
The Seurat package version 2.4 workflow in R (https://github.com/satijalab/seurat) 
was used for transcriptome processing/clustering plots. The data was integrated for batch 
correction using the first 50 canonical components. To separate CD8 and CD4 cells, each cell 
was scored for expression of genes over expressed in clearly CD8 or CD4 cells (by CD8A, 
CD4 transcript count). Cells were then assigned to the group where they had the higher score 
and then split for further processing. The tSNE embedding and clustering was performed on 
the first 20 principal components of the integrated embedding. The cells were clustered using 
shared nearest neighbors (SNN) and the heat maps represent the top over expressed genes of 
each cluster selected by average fold change and p-value on a Wilcox test. Clusters were 
named by picking one gene indicative of their functional status. The Circo plots were 
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generated using a custom code where the inner tree is hierarchical clustering of the mean of 
the transcriptome data for each clonotype. The shared clones between the fresh and grown 
TIL were matched via their TCRa and TCRb nucleotide sequence and then graphed based on 
the relative frequency in each sample.  
TIL Recognition Assays via 4-1BB Upregulation and IFN-γ secretion 
For the PDAC TIL: In triplicate, T cells were put at a 10:1 ratio with their autologous 
tumor target, CAPAN-1 (HLA mismatch control), or media (TIL alone). For some 
experiments the autologous tumor targets were incubated with 80 µg/ml of anti-MHC class I 
antibody (clone W6/32) for 3h prior to addition of T cells, as previously described [219]. 
After 24 h incubation, the supernatants and T cells were collected. TIL were analyzed for 4-
1BB/CD137 expression via flow cytometry. Detection of secreted cytokines in the 
corresponding supernatants were detected  using a V-PLEX Plus Proinflammatory Panel 1 
(human) kit and analyzed on a QuickPlex SQ 120, both available from Meso Scale 
Discovery. Reported values have CVs <20%.  
For the INF-γ ELISPOT: One day prior to the assay, the TIL were thawed and rested 
overnight in TIL-CM with 6000 IU/mL IL-2. Six hours prior to the assay, TIL were washed 
and rested in TIL-CM without IL-2. The tumor lines were put at 1x106 cells/mL and 
incubated with 80 μg/mL of the HLA-ABC blocking antibody or 80 μg/mL of its isotype 
control for 3 hrs in 15 mL conical tubes at 37C. The tumor cells were then added directly to 
the ELISPOT plate. TIL were then put at a 2:1 or 4:1 ratio with an HLA-matched OvCa cell 
line (either SKOV3, COV318, or COV362) in the presence of an HLA-ABC blocking 
antibody, its isotype control, PMA/Ionomycin, or media (TIL alone). The conditions were 
performed in triplicate and the cells were co-cultured for 15 hrs before developing as 
 
50 
 
previously described [220]. Spots on ELISPOT plates were counted with the ImmunoSpot 
machine (Cellular Technology Ltd., Shaker Heights, OH).  
 
Statistical Analysis 
GraphPah Prism v7.0 (GraphPad Software) was used for graphing and statistical 
analysis. Differences between groups or experimental conditions were determined using 
either parametric or non-parametric, two-tailed t-tests (paired or unpaired as appropriate). 
Linear regression and Spearman correlation analyses were also used as indicated. Two-sided 
p-values <0.05 were considered statistically significant and in the figures are indicated as * 
p<0.05, ** p<0.01, *** p<0.001, and **** p<0.0001.  
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Chapter 3: 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth In to a 
Distinct Repertoire Capable Of Tumor Recognition in Pancreatic Cancer 
 
This chapter is based on the original research article “4-1BB Agonist Focuses CD8+ Tumor-
Infiltrating T-Cell Growth In to a Distinct Repertoire Capable of Tumor Recognition in 
Pancreatic Cancer” published by Sakellariou-Thompson et al. in Clinical Cancer Research 
on September 25th, 2017 (DOI: 10.1158/1078-0432.CCR-17-0831). It is presented with 
permission from the American Association for Cancer Research (AACR) as per item 4 of the 
“Article Reuse by Authors” section of the publisher’s Copyright, Permission, and Access 
document which states, in part: 
“Authors of articles published in AACR journals are permitted to use their 
article or parts of their article in the following ways without requesting 
permission from AACR: Submit a copy of the article to a doctoral candidate’s 
university in support of a doctoral thesis or dissertation.”  
 
3.1 Introduction 
 
Pancreatic cancer is the third-highest cause of cancer-related death for men and 
women in the United States and is expected to become the second-leading cause of cancer 
mortality by 2030 [221, 222]. The majority (85%) of pancreatic cancer diagnoses are 
classified as pancreatic ductal adenocarcinoma (PDAC) [223]. Patients afflicted with PDAC 
often present with late-stage cancer and face the poorest prognosis of all cancer types with a 
5-year survival rate of around 6% [224]. Despite efforts to improve treatment, surgery, 
chemotherapy, and radiation remain the only options. These treatment strategies have shown 
limited effectiveness as most patients will recur within a year of treatment even after 
successful tumor resection [224, 225]. Therefore, there is a great need to broaden treatment 
options.  
Immunotherapy has made a tremendous mark in the treatment of cancer, especially in 
the past decade. Its success was first observed in the treatment of metastatic melanoma with 
high-dose IL-2 and then more recently with agents that block CTLA-4 and PD-1 (checkpoint 
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blockade) [43, 226, 227]. These treatments were later transposed to several cancer types, 
including MSI-high cancers regardless of indication [134, 228-235]. In PDAC, however, they 
have been ineffective with no objective response seen with the exception of the very rare 
MSI-high subtype of PDAC [209, 210, 231]. The lack of efficacy could be a result of the 
paucity of CD3+ T-cell infiltrate [236]. An alternative approach to overcome the limitation 
posed by the modest immune infiltrate in PDAC is the ex vivo amplification of TIL for re-
infusion through autologous ACT. 
TIL ACT expands T cells up to several hundred-fold from surgically resected tumor 
and re-infuses them into the patient, providing a large influx of anti-tumor T cells. Our group 
and others have demonstrated its effectiveness in melanoma [94, 108, 237, 238]. With an 
average objective-response rate (ORR) of 50%, TIL ACT is among the best treatment options 
for metastatic disease. The MDACC experience also demonstrated a positive correlation 
between CD8+ TIL infused and response [108]. These results have already spurred efforts to 
translate ACT to other cancer types, and a handful of preliminary studies have reported 
encouraging data in small cohorts of patients in indications such as cervical cancer (33% 
ORR), ovarian cancer (avg PFS 3.7 months; Pederson Oncoimmunol 2018) and 
gastrointestinal malignancies (case studies reported but no ORR yet) [239, 240]. PDAC could 
also potentially benefit from TIL ACT as the presence of CD8+ TIL is associated with greater 
5-year survival [85, 216]. This suggests that endogenous PDAC TIL can exert some degree 
of tumor control, supporting the potential of TIL ACT.  
One of the major challenges faced in growing TIL from GI cancer types for ACT 
trials is the difficulty of expanding CD8+ T cells from the tumor tissue [119, 241]. PDAC has 
a well-characterized immunosuppressive tumor microenvironment that might contribute to 
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the difficulty of triggering the proliferation of cytotoxic CD8+ T cells from this tumor tissue 
and account for their decreased numbers [236, 242]. A method to resolve this barrier is by 
manipulating 4-1BB/CD137, a member of the tumor necrosis factor receptor family, which 
provides a strong co-stimulatory signal for increased activation, proliferation, and survival. 
This receptor is predominantly expressed on recently activated CD8+ T cells with peak 
expression at 24 h [55]. In fact, our group demonstrated that inclusion of an agonistic 4-1BB 
mAb (Urelumab, BMS) in TIL cultures was able to increase melanoma and triple-negative 
breast cancer CD8+ TIL proliferation [220, 243]. Based on this previous work, we posited 
that use of an agonistic 4-1BB mAb in PDAC TIL culture would provide the same benefits of 
increased CD8+ TIL yield. 
Here, we demonstrate that the addition of an agonistic 4-1BB mAb increases the 
ability to grow TIL from PDAC, improves the total yield, and stimulates the proliferation of 
more CD8+ T cells without overly differentiating them. In addition, these CD8+ TIL have a 
distinct TCR repertoire compared to IL-2 only grown TIL and display MHC class I-restricted 
autologous tumor recognition. These results support the use of 4-1BB-expanded TIL in ACT 
strategies for patients with PDAC. 
 
3.2 Results 
3.2.1: PDAC TIL infiltrate is predominantly CD4+ T-cells 
To determine if the immune component of PDAC was sufficient for TIL ACT, we 
assessed the immune infiltrate by performing flow cytometry on manually disaggregated 
samples (n=28). The amount of CD3+ TIL observed was less than 1% of all cells in the tumor 
sample on average as compared to metastatic melanoma with an CD3+ TIL infiltrate >2% 
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(Figure 8A). Quantitative IHC analysis found that the mean density of CD3+ TIL was 314 
cells/mm2 (Figure 8B). This is fewer than what the literature reports for an immunogenic 
cancer like melanoma (422 cells/mm2) [244]. Additionally, metastatic (closed circle) and 
primary (open circle) PDAC samples did not appear to stratify. Further IHC analysis showed 
that all samples displayed ≥50% MHC Class I expression that was homogenous throughout 
the tumor tissue, suggesting that lack of Class I was not the reason for low CD3+ infiltration 
(Figure 8C). We also evaluated the proportion of CD8+ and CD4+ T cells. With an average 
CD8:CD4 ratio of 0.75, CD4+ TIL comprised the majority of the T-cell infiltrate (Figure 8D). 
As a point of comparison, metastatic melanoma showed a CD8:CD4 ratio of 1.5 (Figure 8D). 
This ratio is similar to IHC data also from Erdag et al. that exhibited a CD8:CD4 ratio of 1.6 
[244]. Metastatic and primary sites did not seem to show a difference in CD8:CD4 ratio. 
Phenotypic analysis on the CD8+ T cells determined their activation and differentiation state 
by assessing their expression of CD28 (50% ± 20%), CD45RA (10% ± 6%), PD-1 (45% ± 
12%), and BTLA (20% ± 12%) (Figure 8E). There were not enough primary samples that 
could be compared with metastatic samples to discern a difference in the phenotype of their 
TIL. However, the low frequency of CD45RA expression combined with expression levels of 
the other three markers suggests a relatively activated and not terminally-differentiated 
immune infiltrate.  
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(A) Flow cytometry analysis was performed on freshly disaggregated tumor samples. A 
representative figure showing the gating strategy based on CD3 and live/dead is presented on 
the left. The right graph shows a significantly lower CD3+ immune infiltrate in PDAC as 
compared to metastatic melanoma. (B) IHC analysis quantified the amount of CD3+ 
infiltration in PDAC. (C) IHC analysis showed that >75% of the PDAC tumor tissue 
expresses MHC class I demonstrating HLA Class I expression. (D) CD8/CD4 ratio in fresh 
PDAC sample compared to melanoma. (E) Phenotypic analysis of expression of CD28, 
CD45RA, PD1, and BTLA on CD8+ TIL present in fresh samples. 
 
3.2.2: PDAC shows an enriched T-cell repertoire in the tumor  
Enrichment of T-cell clones at the tumor site in comparison to the blood would 
suggest that the patient is mounting an immunogenic response to its tumor and that specific 
T-cell clones are migrating to the tumor and proliferating in the tissue. To determine the 
tissue-specific distribution of the T-cell repertoire, we sequenced the T-cell receptor beta-
Figure 8. PDAC TIL infiltrate is largely dominated by CD4+ T cells. 
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chain (TCRB) CDR3 region of the T cells present in the blood, tumor and normal tissue from 
seven patients when available (Figure 9).  This analysis, presented as productive clonality, 
revealed that the T-cell repertoire in the tumor is generally more clonal than in the blood 
(Figure 9A). Productive clonality is a measure of the degree to which one or several unique 
clones dominate the repertoire [245]. Linear regression analysis compared the relative 
frequencies of individual TCRB clones present in both the blood and the tumor (Figure 7B). 
All autologous blood-tumor pairs displayed slopes (m) <1, demonstrating a higher frequency 
of shared clones in the tumor than the blood. However, it is possible that high frequency 
clones present in the blood may correlate with high frequency clones present in the tumor. To 
determine the strength of correlation between clones in these sites, clones were partitioned 
and compared as follows using Spearman correlation: top clone frequency defined as ≥ 
0.24% in the tumor (red circles), remaining clones partitioned in half with mid-frequency 
shared clones (green circles) and low-frequency shared clones (blue circles). Interestingly, 
Spearman correlation analysis showed weak or undefined correlation between the frequency 
of T-cell clones in the blood and their frequency in the tumor tissue (rs <0.5), even among 
the top ranking clones in the tumor (red circles). Additionally, there were a few instances 
where the middle-ranking clones in the tumor (green circles) had greater correlation with 
their frequencies in the blood. Only MP31 showed good correlation (rs = 0.61) of the 
frequencies of these top shared clones (Figure 9B). Linear regression analysis was also used 
to compare the relative frequencies of individual TCRB clones present in both the normal 
and tumor tissue (Figure 9C). Similar to the tumor-blood pairs, the slopes for all the tumor-
normal tissue pairs were <1, indicating that individual shared clones were found at higher 
frequencies in the tumor than the normal. In addition, clones were partitioned and correlation 
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calculated in the same manner as described above. In contrast to the tumor-blood pairs, the 
frequencies of the T cells in autologous tumor-normal tissue pairs showed stronger 
correlation among the top and mid-frequency clones. Four of the five pairs (MP64B, MP75, 
MP81, and MP84B) had rs > 0.44 while two of them (MP64B and M75) had rs > 0.5, 
showing that the repertoires were very similar between the tumor and the normal tissue in 
these cases. Also different from the tumor versus blood comparison was that the top clones in 
the tumor (red circles) were often high ranking in the normal tissue as shown by clustering 
along the hashed line. MP31 shared very few clones overall, so it was not partitioned. 
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 CDR3 sequencing of the TCR beta-chain was done on the blood, tumor and normal tissue.  
(A) TCRB clonality is higher in the tumor than the blood for most samples.  (B) Frequencies 
of shared clones in the tumor and blood and (C) tumor and normal tissue are shown.  Top T-
cell clones from the tumor that are also shared between the blood or normal tissue are 
highlighted in red. The remaining shared clones are split in half with the top half colored 
green and the bottom half colored blue. Shared clones (n), linear regression analysis with line 
of best fit (solid line), slope of best-fit line (m), and color-coded Spearman correlation 
coefficient (rS) for each group are next to each graph in (B) and (C). Hatched lines represent 
the identity line, i.e. 1:1 frequency ratio. The data plotted in (B) and (C) was jittered to 
prevent over-plotting. 
 
3.2.3: 4-1BB mAb increases total TIL growth, success rate, and frequency of CD8+ TIL 
Prior work by our group detailed how infusion of melanoma patients with a higher 
proportion of CD8+ T cells and larger amount of TIL in general correlated with better clinical 
response [108]. This result coupled with our observations of a predominance of CD4+ TIL 
and relative scarcity of CD3+ infiltration in general prompted us to consider ways to generate 
greater TIL growth that was rich in CD8+ T cells. Previous work showed that recently 
antigen-activated CD3+CD8+ TIL upregulate expression of the costimulatory molecule 4-
1BB [55]. Furthermore, additional work by our group and others demonstrated that 
stimulation of this pathway through the use of an agonistic anti-4-1BB (a4-1BB) antibody 
could decrease time of TIL culture while increasing total TIL growth, particularly that of 
CD3+CD8+ T cells  [241, 243]. Thus we set up samples for TIL culture where one set of 
fragments received only the conventional high-dose IL-2 (n=28) and the other received high-
dose IL-2 plus the a4-1BB mAb (n=27) (Table 1). The addition of a4-1BB increased the 
average total TIL growth from 40x106 cells for IL-2 alone to 100x106 for IL-2 + a4-1BB 
(Figure 10A). Only cultures that grew in at least one of the two conditions are represented in 
Figure 10A. Additionally, a4-1BB doubled the success rate (14/27; 52%) for TIL growth 
Figure 9. TCRB clonality and frequency of shared TCRB clones higher in tumor 
than autologous blood and normal tissue. 
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from fragments compared to IL-2 only (8/28; 29%) (Table 2). The benchmark for a 
successful TIL culture, 12x106 total cells, was established from scaling down the MDACC 
Clinical Melanoma TIL Lab’s criterion for success where 20 fragments are set up for TIL 
expansion and 40x106 cells is considered the minimum to treat a patient. Some IL-2 only 
cultures did not reach the benchmark and several produced no discernible TIL growth while 
their companion a4-1BB culture produced ≥12x106 cells (Table 1). To that effect, our work 
demonstrates that use of a 4-1BB mAb could rescue cultures that would not have grown 
under the conventional methods.  
Next, we determined whether the cells that grew out of the cultures treated with a4-
1BB were enriched for CD3+ TIL and if CD8+ TIL now comprised the majority of CD3+ T 
cells. In cultures treated with a4-1BB, the total number of CD3+ TIL was significantly 
increased over IL-2 only cultures on average from 30x106 cells to 75x106 cells respectively 
Table 1. TIL from PDAC are mainly CD4+ but a4-1BB switches majority to CD8+ 
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(Figure 10B). Only cultures that grew in at least one of the two conditions are represented in 
Figure 10B. Since NK cells and γδ TCR+ T cells can also express 4-1BB, we stained for their 
presence in primary cultures to determine if the a4-1BB antibody being used was stimulating 
their growth [246, 247]. Indeed we found that three cultures with a4-1BB were enriched with 
a CD3-CD56+ population that was a greater proportion of the culture than CD3+ TIL (Figure 
10C). Likewise, some cultures also showed an increase in γδ TCR+ T cells in a4-1BB 
cultures versus IL-2 alone (Figure 10D, top graph). Only cultures that grew in both 
conditions are represented in Figure 10C and D.  Neither the increase in NK cell growth (p = 
0.203) or γδ TCR+ T-cell growth (p = 0.078) due to 4-1BB co-stimulation was found to be 
significant overall. However, co-stimulation with a4-1BB produced a primary TIL culture 
that was on average 55% CD3+CD8+ TIL and 5% CD4+ TIL. We observed the opposite 
situation in IL-2 alone cultures where 25% of CD3+ TIL were CD8+ and 60% were CD4+. 
Overall, the 4-1BB mAb caused a dramatic switch in the composition of CD3+ TIL towards 
the more favorable CD8+ TIL (Figure 10D).  
 
 
 
 
 
 
 
Table 2. Using a4-1BB increases clinically relevant growth success rate. 
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Tumor fragments were set up with either high dose of IL-2 alone or with the addition of an 
agonistic anti-4-1BB (a4-1BB). (A) Total TIL numbers and (B) total CD3+ TIL expanded 
with or without a4-1BB. Expansion was considered successful with 12x106 cells or more 
(dotted line); cultures which did not reach this number in both conditions are not presented. 
(C) Percentage of CD3+ and CD3- CD56+ TIL grown in each condition. Only cultures with 
successful growth in both conditions are presented. (D) Percentage of  TCR+, CD8+, and 
CD4+ within the CD3+ T cell subset. Only cultures with successful growth in both conditions 
are presented. 
 
3.2.4: Addition of 4-1BB mAb does not overly differentiate CD8+ TIL 
To better understand what effect the augmented growth via 4-1BB mAb stimulation 
had on CD8+ TIL differentiation, we performed phenotypic analysis of CD28, CD45RA, PD-
1, and BTLA expression. Between IL-2 only and a4-1BB cultures, the only significant 
change was a decrease in CD45RA expression (p = 0.031) (Figure 11A). In fact, the level of 
Figure 10. High numbers of CD8+ TIL can be expanded from PDAC with the use of 
agonistic anti-4-1BB antibody. 
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expression of these markers was comparable to that seen on CD8+ TIL in the fresh tumors 
(Figure 6E). Further phenotyping was done using the established memory markers CD45RA, 
CD27, CD28, and CCR7 (Figure 11B) [248]. The vast majority of TIL, regardless of culture 
condition, were CD45RA-CCR7-, indicating that they are effector memory (EM) cells. 
Further characterization of their EM status was done by analyzing differential expression of 
CD27 and CD28, which has been shown to subdivide EM cells into four subsets termed 
EM1, EM2, EM3, and EM4 (Figure 11C) [249].The majority of TIL, again regardless of 
culture condition, fell in the EM3 (CD27-CD28-) subset which Romero et al. have shown to 
display stronger cytolytic activity [249]. We also further explored the degree of 
differentiation with the expression of KLRG1, CD57, Eomes, T-bet and Granzyme B. As 
shown in Figure 12, KLRG1 was absent from both culture conditions. Combined with the 
other markers, this supplementary analysis further testifies that the stimulation of 4-1BB does 
not overly differentiate the cells and leads to the proliferation of effector/memory. Overall, 
this shows that even though a4-1BB stimulates aggressive expansion of activated CD8+ TIL, 
they do not become overly or terminally differentiated. 
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 (A) Percent expression of phenotypic markers (CD28, CD45RA, PD1 and BTLA) for T-cell 
activation and differentiation on CD8+ TIL post-culture evaluated by flow cytometry. (B) 
Comparing expression of CD45RA and CCR7 shows whether TIL are naïve (N), central 
memory (CM), effector memory (EM), or terminally differentiated effector memory that re-
express CD45RA (TEMRA). (C) Comparison of CD27 and CD28 expression shows EM 
subsets of CD8+ TIL grown in each culture condition. Representative dot plots for B and C 
are shown on the right.  
 
 
 
 
 
 
 
 
 
Figure 11. Addition of a4-1BB does not overly differentiate CD8+ TIL. 
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Percent expression of phenotypic surface and intracellular markers (KLRG1, EOMES, 
TBET, CD57 and GRZB) for T-cell effector/memory status of CD8+ TIL post-culture 
evaluated by flow cytometry. 
3.2.5: Expansion of distinct CD8+ T-cell clones favored by a4-1BB mAb compared to IL-2 
alone 
Next, we questioned how the culture conditions affected the repertoire of the TIL that 
grew out by sequencing the TCR of sorted CD8+ T cells and comparing their relative 
frequencies to each other and to their starting frequency in the tumor (Figure 13). Many 
clones are shared (red lines) between the tumor and both TIL culture conditions. However, 
these clones are present at different frequencies between the conditions, as demonstrated by 
the position of the lines where further away from center denotes higher frequency. This 
shows that the addition of a4-1BB mAb favors expansion of unique clones as compared to 
IL-2 alone. This is further suggested by the presence of several T-cell clones that are shared 
between the tumor and only one of the culture conditions (blue lines). Finally, sequencing 
detected some clones that were not present in the tumor but were either present in only one 
culture (black lines) or shared only between the two culture conditions (green lines). Overall, 
in 4/5 patients, the addition of a4-1BB mAb in the culture expands a greater number of CD8+ 
TIL but focuses their repertoire as evidenced by the smaller number of TIL clones in the a4-
1BB cultures than the IL-2 alone cultures.  
Figure 12. Addition of a4-1BB does not lead CD8+ TIL into senescence. 
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CDR3 sequencing of the TCR beta-chain was done on the blood, tumor and expanded TIL 
(CD8+ sorted).  Relative frequency in each sample is indicated along each axis of the hive 
plot with frequency increasing away from the center.  Red lines indicate TCRB clones shared 
between all three samples, blue lines for those shared between one culture condition and the 
tumor, green for those shared only between the culture conditions and finally black lines 
indicate TCRB clones found in only one condition. Total TIL grown and number of unique 
clones in each condition are shown.  
 
3.2.6: PDAC CD8+ TIL recognize autologous tumor targets  
Given the distinct repertoire generated by each culture condition, the anti-tumor 
potential of both IL-2 only and IL-2 + a4-1BB cultured PDAC CD8+ TIL was assessed. To 
this end, sorted CD8+ TIL lines from both conditions were rapidly expanded (REP) and co-
cultured for 24 h with autologous tumor targets derived from patients MP81 and MP64B 
(Figure 14). Bulk TIL initially expanded using a4-1BB in combination with IL-2 were also 
put through the REP process and achieved the expected fold expansion (500x – 1500x) after 
14 days, confirming that both sorted CD8+ and bulk populations could exponentially grow 
after being propagated with a4-1BB (Figure 15).  Prior to co-culture setup, autologous tumor 
cells and CAPAN-1, a HLA-mismatched pancreatic tumor line for MP81, were stained for 
MHCI expression (HLA-ABC) (Figure 16). Autologous tumor cells were found to express 
low, but detectable levels of MHCI as compared to the CAPAN-1 cells (MFI: MP81 467, 
MP64B 606  vs 5387 for CAPAN-1). In spite of this low level of MHCI expression, both IL-
2 grown and a4-1BB grown MP81 TIL secreted more IFN-γ in the presence of the 
autologous target than with CAPAN-1 (Figure 14A). Upregulation of 4-1BB on CD8+ T cells 
has been incorporated in tumor recognition assays previously [240, 250]. As such, both 
MP81 TIL lines significantly upregulated 4-1BB expression after exposure to the tumor 
target as compared to with the CAPAN-1 control Figure 14B and C). The upregulation of 4-
Figure 13. Distinct TCR repertoires are favored in each culture condition. 
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1BB was particularly high on the CD56+ T-cell subset, a cytotoxic T-cell subset [251]. Given 
that the 4-1BB expression was higher in the CD56+ CD8+ MP81 TIL subset, we assessed 
MHCI-restricted recognition by blocking MHCI on its tumor target (Figure 14D and E, left 
panels). It was observed that most of the recognition in the total CD8+ population was 
MHCI-restricted for both culture conditions. This experimental setup was repeated with an 
additional TIL and autologous tumor target (MP64B) with similar observations (Figure 14D 
and E, right panels). Taken together, the IFN-γ secretion and elevated 4-1BB expression 
indicate there are MHC class I-restricted tumor-reactive CD8+ T cells in the PDAC TIL 
repertoire. 
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(A-C) Sorted MP81 CD8+ TIL grown in IL-2+a4-1BB or IL-2 only were co-cultured for 24 h 
with autologous tumor, HLA-mismatched tumor line CAPAN-1, or media (TIL only).  All 
conditions were in triplicate. (A) IFN-γ secretion was measured as well as (B, C) 
upregulation of 4-1BB on CD56+CD8+ TIL.  Part (B) shows the compiled results of dot plot 
analysis of 4-1BB upregulation visualized by flow cytometry and (C) shows representative 
dot plots of 4-1BB upregulation. Results for a4-1BB grown TIL and IL-2 only grown TIL are 
from separate experiments. (D, E) Sorted MP81 CD8+ TIL (left graphs) and sorted MP64B 
CD8+ TIL (right graphs) grown in IL-2+a4-1BB or IL-2 only were co-cultured for 24 h with 
autologous tumor, pre-treated with MHC-I blocking antibody (W6/32) or isotype control 
(IgG2a), or media (TIL only). All conditions were in duplicate or triplicate. Part (D) shows 
the compiled results of dot plot analysis of 4-1BB upregulation visualized by flow cytometry 
for MP81 CD8+ TIL (left graph) and MP64B CD8+ TIL (right graph). (E) shows 
representative dot plots of 4-1BB upregulation.  
 
 
 
 
 
 
(A) Sorted PDAC CD8+ TIL (IL-2 alone or a4-1BB + IL-2) and (B) bulk a4-1BB stimulated 
PDAC TIL were rapidly expanded and their fold expansion calculated on Day 14. 
 
 
Figure 14. Reactivity of PDAC TIL to an autologous tumor target. 
Figure 15. Fold expansion of bulk and CD8+ PDAC TIL following the REP. 
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Figure 16. Level of MHC class I expression on PDAC tumor cell lines. 
HLA-A,B,C expression was assessed using flow cytometry on autologous PDAC tumor cell 
lines as well as on a commercially available PDAC tumor cell line (CAPAN-1). Unstained 
tumor cells were used as a control (red histogram). The mean fluorescence intensity (MFI) of 
MHC class I expression for each line assessed is shown in the legend. 
 
 
3.2.7: Further improvement of TIL culture process for PDAC with a 3-signal approach 
As just shown above, the manipulation of 4-1BB through agonistic stimulation 
(Urelumab, BMS), increased CD8+ TIL proliferation and improved culture success in 
pancreatic cancer. Additional work to further improve the TIL culture method was performed 
by our group which led to the development of a new methodology utilizing an anti-CD3 
antibody (OKT3) in the early TIL culture as well as transitioning to TIL culture in a gas-
permeable culture flask (GREX) to expand melanoma TIL [218]. The application of this 
novel strategy, named TIL 3.0, to PDAC TIL culture led to the expansion of a greater 
number of CD3+ TIL (200x106 average) compared to IL-2 only and IL-2+a41BB culture 
methods (Figure 17A). This increase in CD3+ TIL number is characterized by a consistent 
maintenance of the high percentage of CD8+ TIL (Figure 17B) and low percentage of CD4+ 
TIL (Figure 17C). The TIL 3.0 method also consistently reduced the time of culture from a 
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period of 3-5 weeks for IL-2 only and IL-2+a41BB to 2-3 weeks (Figure 17D). Finally, TIL 
3.0 drastically increased the overall success rate of establishing an PDAC TIL culture from 
29% (10/34) for IL-2 only and 48% (16/33) for IL-2+a41BB to 95% (19/20) for the IL-
2+OKT3+a41BB method (Figure 17E). The benchmark for a successful TIL culture, 12x106 
total cells, was established from scaling down the MDACC Clinical Melanoma TIL Lab’s 
criterion for success where 20 fragments are set up for TIL expansion and 40x106 cells is 
considered the minimum to treat a patient [252]. 
 
Figure 17. Characterization of PDAC TIL growth across culture conditions. 
Comparison of the (A) total CD3+ TIL number, (B) percentage of CD3+CD8+ TIL, and (C) 
percentage of CD3+CD4+ TIL generated between the different culture methods. Comparison 
between culture methods of the (D) time of culture and (E) success rate of growth for all 
attempted cultures.  
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3.2.8 Synchronous stimulation of 4-1BB and CD3 prevents CD8+ TIL over differentiation 
To understand how the different culture methods affected the CD8+ TIL, the 
expression of CD28, BTLA, and PD-1 were explored as surrogates for T-cell activation and 
differentiation (Figure 18). These 3 markers were strategically selected for the power of 
assessment they provide individually as well as together. BTLA+CD8+ TIL have been 
reported by our group to be less-differentiated cells, capable of prolong persistence and serial 
killer capacities [188, 189]. Expression of CD28 is also a trait of lesser differentiation, while 
the expression of PD1 is increased with chronic antigen exposure and exhaustion, thus 
signifying later stage of differentiation [249, 253]. When comparing expression of the 3 
markers on PDAC TIL expanded with IL-2 only or IL-2+a41BB, no significant difference 
was observed. However, CD8+ TIL grown with the TIL 3.0 method were comprised of a 
significantly greater percentage of cells expressing BTLA and CD28, and a significantly 
smaller percentage of CD8+ TIL expressing PD-1, altogether suggesting a less differentiated 
profile (Figure 18).  
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Comparison between the different culture methods of the percentage of CD28, BTLA, and 
PD-1 expressing CD8+ TIL generated. 
 
3.3: Summary 
In this chapter, it was shown that PDAC has a scarce, yet activated CD8+ TIL 
infiltrate that is preferentially expanded with the addition of an agonistic 4-1BB mAb to the 
TIL culture. The a4-1BB mAb consistently augmented total TIL numbers and doubled the 
success rate of TIL growth without overly differentiating them in spite of the aggressive 
proliferation spurred by 4-1BB costimulation. Finally, despite the fact that the a4-1BB mAb 
favored expansion of distinct CD8+ T-cell clones from the tumor in comparison to IL-2 
alone, TIL derived with either culture condition showed tumor recognition via IFN-γ 
secretion and 4-1BB upregulation. While only two TIL lines and paired autologous tumor 
targets were able to be tested, it was observed that there was a higher frequency of anti-tumor 
reactive CD8+ TIL in the a4-1BB grown cultures compared with TIL grown in IL-2 alone. 
Further improvements to the culture process by the addition of an agonistic 4-1BB mAb and 
OKT3, a novel 3-signal approach, increased the ability to grow TIL from PDAC, improves 
the total yield, and stimulates the proliferation of activated CD8+ T cells. Using the TIL 3.0 
methodology to grow PDAC TIL brought about several major improvements; 1) reduce the 
manufacturing time, 2) increase the success rate to over 90%, 3) require less tumor tissue 
(only 5 tumor fragments, or the equivalent of 2 core needle biopsies). In the context of a 
clinical trial, these improvements would make it possible to grow enough TIL to treat over 
90% of the enrolled patients with a product consistently high in CD8 content. These results 
suggest that the a4-1BB mAb can facilitate TIL ACT for PDAC by increasing the final yield 
of the desirable, anti-tumor CD8+ T cells clones present in PDAC. 
Figure 18. Phenotyping of grown PDAC TIL across culture conditions. 
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Chapter 4: Heterogeneity of Pancreatic Cancer Tumor-Infiltrating Lymphocytes at the 
Single-Cell Level 
 
4.1: Introduction 
 
 While exploring the TCR repertoire in PDAC in the previous chapter, high frequency 
T-cell clones overlapping between the tumor and uninvolved-tissue were observed, 
potentially suggesting the presence of tissue-resident memory T cells (TRM). TRM are a unique 
population of T cells that don’t recirculate between the tissue and periphery, and their 
importance has only been elucidated within the past decade [254]. Instead, they are small 
population of memory T cells that take up residence in peripheral tissues (e.g. skin, lungs, GI 
tract) sites after trafficking there as a part of an immune response. By doing so, they can 
function as a rapid response arm of the adaptive immune system to quickly engage any re-
challenge. After pathogen clearance, signals in the local tissue environment, such as TGF-β 
or IL-15, help promote a change in transcriptional programming that results in engraftment of 
long-lived TRM population [255]. This TRM profile is typically characterized by upregulation 
of genes associated with tissue retention (CD103, CD69, CD49a/ITGA1) and longevity (Bcl-
2, CD127/IL7Ra) coupled with downregulation of genes associated with tissue egress 
(S1PR1/5, L-selectin/CD62L, CCR7, KLF2) [256].  
The role of TRM was first appreciated in the context of infection as they were found to 
mediate a novel mechanism of immunity that involved non-migratory T cells in barrier 
tissues [257-259]. However, in recent years the importance of TRM in cancer immunity has 
also been uncovered [260]. Several reports have demonstrated that the presence of TRM, 
particularly CD103+CD8+ TRM, is correlated with improved survival in several epithelial 
cancers [261-267]. The reason this correlation has been found predominantly in epithelial 
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cancers is due to the fact that epithelial tissues express TGF-β, which induces CD103 
expression on T cells, and the only known ligand for CD103 is the epithelial-associated 
protein E-cadherin and is expressed on epithelial cells [260, 268]. The interaction between 
CD103 on T cells and E-cadherin on tumor cells could play an important role in tumor 
control as in vitro studies have shown that it is important for immune synapse formation and 
subsequent release of cytolytic granules [269, 270]. Additionally, these TRM cells have also 
been shown to harbor increased cytotoxicity, be composed of the tumor-reactive CD8+ TIL, 
and have higher expression of checkpoint markers [261, 262, 264, 271-273]. In pancreatic 
cancer, an in vitro study showed that CD103+CD8+ T cells more efficiently adhered to E-
cadherin expressing tumor cells, thus allowing for increased cytolysis [274]. Given the 
emerging importance of TRM in tumor control as reported in the literature as well as the hint 
at their presence in our own study, we wanted to further explore TRM in PDAC.  
To capture the breadth of the TRM phenotype in PDAC, we turned to multi-parameter 
flow cytometry and single-cell RNA-sequencing (scRNAseq) for their ability to provide a 
detailed understanding of diverse cell populations. scRNAseq in particular has emerged as a 
powerful tool for immunological studies given the extreme heterogeneity of immune cells. T 
cells are no exception to this, as their heterogeneity is governed by not only various 
transcriptomic profiles that direct their development and differentiation, but also the diversity 
of their TCRs. scRNAseq provides the means to asses a complex, and yet-to-be-fully-
defined, cell population like TRM cells in an unbiased manner. Several studies have been 
published in the last few years showing the power of scRNAseq to identify novel T-cell 
phenotypes in different cancers [262, 275-280]. This approach is particularly attractive for 
exploring TRM in PDAC due to the lack of a defined phenotype in this cancer type as well as 
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PDAC’s overall low-level of immune infiltration. Therefore, we sought to explore the PDAC 
TRM population by combining high-order flow cytometry, scRNA transcriptomic and TCR 
sequencing.  
4.2: Results 
4.2.1 Exploring tissue-resident memory T cells in PDAC via CD103 expression 
To initially determine the presence of TRM in PDAC, a subset of primary PDAC 
samples (n=10) were analyzed using multi-parameter flow cytometry (Figure 19). In the 
literature, the TRM population is typically characterized by expression of integrin αE (ITGAE, 
also known as CD103), which is a well-characterized marker for TRM cells, as well 
expression of several activation and checkpoint markers (CTLA4, PD-1, LAG3, TIM3 ICOS, 
and Ki67). The majority of CD103 expression was found on CD8+ TIL with almost no 
expression found on CD4+ TIL in freshly disaggregated primary tumor tissue (Figure 19A 
and 19B). This is similar previously published data in OvCa showing that the CD103+ TRM 
population is mainly within the CD8+ TIL compartment [266]. To better understand the 
relative abundance of CD103 expression in PDAC, OvCa TIL were used as a point of 
comparison due to the reported presence of CD103+ TRM in the literature (Figure 19C) [261]. 
Based on the percentage of CD103+ expression, PDAC was found to have about half as much 
TRM on average as OvCa (21% vs. 45% respectively). The CD8+ TIL showed a large fraction 
of PD-1+ and Ki67+ cells compared to the other markers (Figure 19A). To determine if these 
markers were preferentially co-expressed with CD103, the differential expression between 
CD103+ and CD103- CD8+ TIL was explored (Figure 19D). Compared to CD103-CD8+ TIL 
(non-TRM), the CD8 TRM population showed only a trend for higher PD-1expression but 
nothing statistically significant.  
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Expression of the TRM marker CD103 and several activation/inhibitory markers on (A) CD8+ 
TIL and (B) CD4+ TIL. (C) Comparison of the CD8+CD103+ TIL fraction in PDAC and 
OvCa. (D) Comparison of activation and inhibitory markers on CD8+CD103+ or 
CD8+CD103- TIL.  
 
Figure 19. Flow cytometry analysis of tissue-resident memory T cells in PDAC. 
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4.2.2 Transcriptomic characterization of TIL isolated from primary pancreatic tumors  
 The lower proportion of of TRM based on CD103 expression in PDAC could be due to 
the fact that it reportedly marks this T cell population mainly in barrier or mucosal tissues 
(such as found in OvCa). Moreover, the literature indicates that TRM do not always express 
CD103 [281]. This fact coupled with the self-limitation of flow cytometry panel using a 
small number of selected markers prompted us to turn to an unbiased and more 
comprehensive approach to elucidate the phenotype of TRM in PDAC. To interrogate this 
phenotype in an unbiased manner, single-cell RNA sequencing was performed on 1,616 
CD3+ TIL (922 CD8+ and 694 CD4+) freshly isolated from 6 primary PDAC samples (Figure 
20). The patient characteristics for sequenced samples are presented in Table 3.  
 
Figure 20. Schematic of sample processing for single-cell RNA sequencing. 
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After sample processing, the data was clustered unbiasedly using t-distributed 
stochastic neighbor embedding (t-SNE) in collaboration with Aislyn Schalck in Dr. Nick 
Navin’s lab (Figure 21 and 22). Four CD8+ TIL clusters (CD8_C1 EOMES, CD8_C2 
ZNF683, CD8_C3 GZMB, and CD8_C4 STAT1) and 3 distinct CD4+ TIL clusters (CD4_C1 
TCM, CD4_C2 Treg, and CD4_C3 TEM) were identified (Figure 21A and 22A). While 3/6 of 
the samples provided the majority of the cells, the relative proportions of each cluster type 
within each sample were similar to each other (Figures 21B and 22B). This indicated that the 
clusters were comparable across the 6 samples.  
 When focusing on the CD8+ clusters, the CD8 TIL seems to be composed of several 
activated or cytotoxic populations based on expression of several markers (Figure 21C). 
CD8_C1 has expression of several MHC Class II alleles plus GZMK, which are markers of T 
cell activation. CD8_C2 has high expression of CD69, a well-known activation marker. 
CD8_C3 appears to be a cytotoxic effector cell population based on expression of GZMB, 
GNLY, PRF1, and NKG7. Finally, CD8_C4 has high expression of Type I interferon (IFN-I) 
response genes (IFIT1, IFIT3, IRF7, STAT1), suggesting exposure to IFN-1 which has been 
shown directly and indirectly promote activation and proliferation of CD8+ T cells. As 
Table 3. Patient characteristics for sequenced tumor samples. 
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hypothesized, based on the low CD103 expression found by flow cytometry, no TRM cluster 
defined by CD103 appeared within the CD8 population. Instead, we found a potential TRM 
cluster that was defined by expression of ZNF683 and CD69 (Figure 21C). While CD69 is 
primarily thought of as a marker of activation, it has also been found to mark TRM T cells. 
More importantly, however, is the expression of the transcription factor ZNF683 (also known 
as Hobit, or homolog of Blimp-1 in T cells) which is reported to be important for TRM 
formation. Furthermore, high expression of CD69 and ZNF683 was coupled with low 
expression of KLF2, S1PR5, and ZEB2 (Figure 21C). This expression profile is similar to 
that described for TRM cells in the literature [255, 278, 282]. Finally, expression of 
checkpoint molecules PD-1 or TIM3 were not associated with the TRM, which is in contrast to 
published observations from other cancer types.  
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(A) t-SNE plot of 922 CD8+ TIL colored by patient and demarcated by colored circles 
indicating four distinct clusters based on gene expression differences. (B) Bar graphs 
showing the cell number contributed by each sample to a cluster (left) and its relative 
proportion (right) (C) Heatmap from single-cell RNAseq unsupervised clustering analysis 
defines 4 clusters as indicated by colored bars along the x-axis. Figure generated in 
collaboration with Aislyn Schalck and Dr. Nick Navin and used with their permission.  
 
  
Within the CD4 population, CD4_C1 surprisingly had expression of CCR7 and TCF7 
which are indicative of a central memory T cell population (Figure 22C). Given that TCM are 
not frequently found at tumor sites, this population is likely contamination from circulating 
CD4 T cells in the blood that may have been passing through the tumor. While Tregs were 
not detected at a high level by flow cytometry (Figure 19B), the CD4_C2 population appears 
Figure 21. Characteristics of CD8+ TIL populations in primary PDAC 
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to be a robust and activated Treg population based on expression of the classical Treg 
markers FOXP3 and CD25 as well as the activation markers GITR, OX40, TIGIT, CD39, and 
4-1BB. Interestingly, the Treg population also had high expression of IL-32, typically known 
as a pro-inflammatory cytokine. Finally, CD4_C3 contained an activated Th1 CD4 subset as 
evidenced by expression of CD40LG, CD69, and IL-2 (Figure 22C). In addition, the cells 
from this cluster may harbor some effector cell functions based on expression of granzyme A 
and K.  
(A) t-SNE plot of 694 CD4+ TIL colored by patient and demarcated by colored circles 
indicating three distinct clusters based on gene expression differences. (B) Bar graphs 
showing the cell number contributed by each sample for each cluster (left) and its relative 
proportion (right) (C) Heatmap from single-cell RNAseq unsupervised clustering analysis 
reveals 3 clusters as indicated by colored bars along the x-axis. Figure generated in 
collaboration with Aislyn Schalck and Dr. Nick Navin and used with their permission. 
Figure 22. Unsupervised clustering of CD4+ single cell transcriptomes. 
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4.2.3 Characterization of TIL clonal repertoire in the tissue  
 In addition to transcriptomic sequencing of the TIL, single-cell TCR sequencing was 
performed in order to compare the frequency of clonal populations with the transcriptomic 
profile they have. Enrichment of a certain clonal population at a tumor site in indicative of 
that population participating in an immune response. To that end, Circos plots were 
generated for the CD8 and CD4+ TIL separately (Figure 23 and 24). The inner ring is color-
coded by sample, the next ring is color-coded by transcriptomic cluster, and the grey outer 
ring contains bars that indicate the relative frequency of that TCR clone. The CD8+ TIL 
Circo indicates that the clones that are enriched at the tumor site (found in numerous copies, 
delineated by the tall grey bars on the outer circle) mainly come from clusters CD8_C1 
EOMES and CD8_C2 ZNF683, while the other two clusters show little to no enrichment of 
clones within them (Figure 23). On the other hand, the CD4+ TIL Circo plot shows little 
clonal expansion of clones overall (Figure 24). Of the clones that show some measure of 
expansion, the majority are in the CD4_C2 Treg cluster followed by a few in the CD4_C3 
TEM cluster. While only one or two samples seem to have most of the clonal CD8 expansion 
detected, the CD4 clonal expansion appears to be spread more evenly among the samples.  
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The inner ring is color-coded by sample, the next ring is color-coded by transcriptomic 
cluster, and the outer ring contains bars that indicate the relative frequency of that TCR 
clone. Figure generated in collaboration with Aislyn Schalck and Dr. Nick Navin and used 
with their permission. 
 
 
 
 
 
Figure 23. CD8+ TIL Circos plot combining transcriptomic profile with TCR frequency. 
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The inner ring is color-coded by sample, the next ring is color-coded by transcriptomic 
cluster, and the outer ring contains bars that indicate the relative frequency of that TCR 
clone. Figure generated in collaboration with Aislyn Schalck and Dr. Nick Navin and used 
with their permission. 
 
 
 
 
 
 
Figure 24. CD4+ TIL Circos plot combining transcriptomic profile with TCR frequency. 
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4.2.4 TIL 3.0 produces a large proportion of cytotoxic and proliferative CD8+ TIL  
 To better understand the effect of the TIL 3.0 culture method on the TIL generated, 
expanded TIL products from the same tissues that were initially sequenced were also sent for 
transcriptomic and TCR scRNAseq (MP108, MP109, MP112, MP115, MP116, and MP121; 
Figure 25A). Initial tSNE anlaysis revealed 7 populations, which were classified based on 
unsupervised heatmap clustering: C1_CD4-OX40, C2_CD8-GZMB, C3_CD3-CYCLING, 
C4_CD3-DYING, C5_γδ-TCELL, C6_CD4-MHCII, and C7_CD8-HSP (Figure 25B and 
25C). Based on the tSNE clustering, the major populations present were a cytotoxic CD8 
cluster (CD8_GZMB) defined by expression of GZMB and PRF1, and a proliferative T cell 
population (CD3_CYCLING) defined by expression of cell-cycle related genes like KI67, 
TUBB, and TOP2A (Figure 25C). Furthermore, it is apparent that the proliferating cell 
population is mainly coming from the cytotoxic CD8 cluster based on proximity and shape of 
the CD8-GZMB and CD3-CYCLING clusters (Figure 25B). The fact that these are the two 
main populations meshes well with the previous observation that TIL 3.0 produces a large 
TIL product that consists mainly of activated CD8+ TIL (Figure 17 and 18). In addition to the 
major activated CD8-GZMB cluster, a smaller CD8 cluster (C7_CD8-HSP) was found that is 
curiously characterized by expression of several heat-shock proteins (HSPs) which are 
chaperone proteins known for promoting cell survival under stress conditions.  
While the majority of TIL produced by TIL 3.0 are CD8+ T cells, there were also two 
small clusters of activated of CD4+ TIL (C1_CD4-OX40 and C6_CD4-MHCII) as well as a  
γδ T cell cluster (C5_γδ-TCELL) (Figure 25B). The larger of the CD4 clusters (C1_CD4) 
had, surprisingly, an activated phenotype as defined by expression of CD40LG, TNFRSF4 
(OX40), and TNFRSF18 (GITR) (Figure 25C).  The minor CD4 cluster (C6_CD4) was 
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defined by high expression of several MHCII alleles as well as expression of IL5 and IL13. 
Since γδ T cells can be stimulated by a41BB, a small component of these TIL were detected 
in the TIL products. This γδ T cell cluster, C5_γδ-TCELL, was defined chiefly by expression 
of TRDC (γδ TCR) but also had expression of genes associated with activation like GNLY, 
CCL3 (MIP1a), XCL1, and XCL2. Finally, a cluster of cells was detected (C4_CD3-DYING) 
that had increased expression of mitochondrial genes, which indicates they are likely 
undergoing apoptosis.  
 (A) Tissue from the same samples that were sent for scRNAseq of fresh TIL were used to 
generate a TIL product using the TIL 3.0 protocol. tSNE clustering (B) and unsupervised 
clustering (C) were generated from the transcriptomic data, revealing 7 transcriptomic 
clusters. Figure generated in collaboration with Aislyn Schalck and Dr. Nick Navin and used 
with their permission. 
Figure 25. Transcriptomic scRNAseq of grown PDAC TIL. 
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4.2.5 TIL 3.0 maintains high frequency clones from activated TIL populations  
 Previous work presented in Chapter 3 Section 3.2.5 looked at the frequency of clones 
in the fresh tumor in comparison to their frequency in the TIL product after culture with IL-
2+a41BB. This TCR sequencing analysis revealed that high frequency clonotypes in the 
tissue did not necessarily expand to a proportionally high frequency in the in the TIL product 
and vice versa. To explore how this relationship might change with TIL 3.0, which now 
includes an additional stimulation with OKT3, the frequency of clonotypes in the fresh tumor 
(Fresh TIL, black) and TIL product (Grown TIL, blue) were compared (Figure 26). Analysis 
of sequencing data found TIL 3.0 is able to maintain the original frequency of clones found 
in the tumor tissue. In other words, if a clonotype was at a high frequency in the tissue it was 
also a high proportion of the grown TIL.   
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Figure 26. Preservation in the TIL product of the initial clonal dominance in fresh 
tissue. 
Six TIL products were TCR scRNAseq’d and the relative frequency of their clonotype 
repertoire was compared to that found in the tissue. The clonotypes from the fresh TIL are in 
black and the grown TIL are in blue. The number of clonotypes in each increases up the y-
axis. Along the x-axis, starting in the middle at 0 in either direction, the relative frequency in 
the grown TIL (blue) or fresh TIL (black) increases. The number of clonotypes detected in 
the grown TIL product for each sample is also shown. Figure generated in collaboration with 
Aislyn Schalck and Dr. Nick Navin and used with their permission. 
 
 The process of TIL expansion alters the transcriptome of TIL. To track TIL 
transcriptomic features through expansion, we made use of the TCR sequence information to 
link transcriptomes pre and post expansion (Figure 27). Figure 27A represents the expanded 
clones, mapped to their initial cluster in the fresh tissue (Figure 27B), where solid circles 
represent clones that expanded and shaded circles represent clones that did not expand (i.e., 
were not found in expanded TIL). The CD8 clusters in the tSNE plot are color coded to 
correspond with the phenotypic groups in the heatmap. Expanded clones were found to come 
from all four phenotypic clusters that were identified, particularly the CD8-EOMES and 
CD8-ZNF683 clusters (Figure 27A). In Figure 27A and 27B, the same tSNE clustering and 
heatmap are shown as in Figure 21C. 
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Figure 27. Comparison of the phenotypic profile from which the grown TIL were 
generated. 
 (A) tSNE clustering of fresh CD8 TIL, where closed circles indicate the clone was detected 
in the grown TIL product and open circle indicates it was not detected. The clusters are also 
color coded to match the phenotypic profiles displayed in (B) the heat map. Figure generated 
in collaboration with Aislyn Schalck and Dr. Nick Navin and used with their permission. 
 
4.3: Summary 
 
 In summary, initial flow cytometry on several fresh, primary PDAC samples data did 
not detect a substantial tissue-resident memory T cell population as classically defined by 
having expression of CD103 and checkpoint markers. However, single-cell RNA 
transcriptomic sequencing allowed for unbiased analysis of the TIL heterogeneity in these 
samples. Transcriptomic sequencing revealed 4 distinct CD8+ TIL clusters and 3 distinct 
CD4+ TIL clusters. While there is variability in the TIL infiltration, the relative proportion of 
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these clusters is similar across patients. Additionally, scRNAseq was able to identify cell 
populations that were not appreciated by flow cytometry, such as a CD69+ZNF683+ TIL 
population that may represent the true phenotype of TRM-like CD8+ T cells found in PDAC as 
compared to the classically-defined phenotype with CD103. Furthermore, sequencing 
revealed a highly activated Treg population that would have otherwise been overlooked if the 
analysis was based solely on flow cytometry data.  Finally, paired single-cell TCR 
sequencing revealed that, although there was not a substantial amount of clonal TIL 
expansion, the majority of this expansion belonged the potentially important CD8+ TRM and 
the CD4+ Treg populations. Using this paired TCR-transcriptome sequencing data to analyze 
the TIL grown with TIL 3.0 showed the major populations that compose the TIL product are 
an activated and cytotoxic CD8 population that is proliferating. Additionally, the TCR 
sequencing data shows that, notably, TIL 3.0 is able to expand CD8+ TIL from the high 
frequency and activated clonotypes. Overall, this analysis shows the potential of combining 
multi-parameter flow cytometry and scRNAseq in defining the heterogeneity of TIL in 
PDAC. 
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Chapter 5: Potential clinical application of tumor-infiltrating lymphocyte therapy for 
ovarian epithelial cancer prior or post-resistance to chemotherapy 
 
This chapter is based on the original research article “Potential clinical application of tumor-
infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to 
chemotherapy” published by Sakellariou-Thompson et al. in Cancer Immunology, 
Immunotherapy on October 10th, 2019 (DOI: 10.1007/s00262-019-02402-z). It is presented 
with permission from Springer as per sections 4a and 4c of the “Authors’ Retained Rights” 
section of the Copyright Transfer Statement document which states, in part: 
 
“Author(s) retain the following non-exclusive rights for the published version 
that, when reproducing the Article or extracts from it, the Author(s) 
acknowledge and reference first publication in the Journal:  
 
(a) to reuse graphic elements created by the Author(s) and contained in the 
Article, in presentations and other works created by them;  
(c) to reproduce, or to allow, a third party Assignee to reproduce the Article 
in whole or in party in any printed volume (book or thesis) written by the 
Author(s).” 
 
5.1: Introduction 
 
Epithelial ovarian cancer (OvCa) is the deadliest gynecological cancer, and is 
estimated to account for almost 14,000 deaths in 2018 [283]. Although prognosis of early-
stage OvCa is favorable,  70% of patients are diagnosed with advanced and metastatic 
disease [284]. Traditional management of advanced stage OvCa includes tumor reductive 
surgery and adjuvant platinum-taxane chemotherapy, which results in high rates of initial 
complete response. However, nearly 90% of patients recur and the 5-year survival rate for 
late-stage disease is only 28% [285, 286]. 
Nevertheless, OvCa possesses a strong immune infiltrate that could provide an 
avenue to greater treatment efficacy and better long-term survival in the context of 
immunotherapy. Several groups have shown that the presence of CD8+ TIL is associated with 
a greater 5-year survival in OvCa, suggesting that CD8+ TIL exert some degree of tumor 
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control [85, 216, 287-291]. This provides a rationale for the use of immunotherapy to harness 
the anti-tumor potential of this immune infiltrate. Checkpoint blockade immunotherapy has 
already made a tremendous mark in the treatment of cancer. Its success was first observed in 
the treatment of metastatic melanoma with agents that block the CTLA-4 and PD-1 axis [43, 
226, 227, 292, 293]. This approach was later transposed to non-small cell lung cancer and 
renal cell carcinoma [228-230]. Unfortunately, the success of checkpoint blockade has not 
been reproduced in OvCa to date [210, 294, 295]. 
Since in vivo manipulation of the TIL through checkpoint blockade does not seem to 
be sufficient to generate a strong clinical response, approaches involving ex vivo 
manipulation of immune cells, such as adoptive cell therapy (ACT) using autologous TIL, 
might be able to provide a large quantity of anti-tumor T cells needed for tumor control. Our 
group and others have demonstrated the effectiveness of TIL ACT in metastatic melanoma 
[94, 95, 108, 237]. With objective response rates (ORR) of 40-50% in metastatic melanoma, 
TIL ACT is among the best treatment options for this patient population. In the 1990s, 
several groups attempted to transpose TIL ACT to OvCa either alone or in combination with 
chemotherapy, or in the adjuvant setting after debulking surgery [296-300]. These early trials 
had some promising results but suffered from a few limitations. Later studies demonstrated 
the need for lymphodepleting pre-conditioning regimens for long term TIL engraftment and 
improved cell generation methodologies that resulted in the infusion of patients with greater 
cell numbers [301]. Furthermore, improvements in techniques for TIL enrichment and 
activation, mainly for CD8+ TIL as they have been correlated with clinical response in 
melanoma, may increase favorable clinical outcomes in OvCa TIL trials [95, 108]. 
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   As stated previously, the manipulation of 4-1BB/CD137 through agonistic 
stimulation (Urelumab, BMS), increased CD8+ TIL proliferation in melanoma, triple 
negative breast cancer and pancreatic cancer [220, 243, 252]. Additional work to further 
improve the culture method was also done by adding an anti-CD3 antibody (OKT3) to the 
early TIL culture as well as transitioning to TIL culture in a gas-permeable culture flask 
[218]. Here, the addition of an agonistic 4-1BB mAb and OKT3, a novel 3-signal approach, 
increases the ability to grow TIL from OvCa, improves the total yield, and stimulates the 
proliferation of activated CD8+ T cells. In addition, these CD8+ TIL displayed HLA-
restricted tumor recognition. These results support the use of TIL expanded with a41BB and 
OKT3 in ACT strategies for patients with OvCa.  
 
5.2 Results for OvCa TIL 
5.2.1 Primary and metastatic OvCa TIL infiltrate is predominantly CD8+ T-cell rich 
The lymphoid immune infiltrate was assessed at the onset of the culture by 
performing flow cytometry on manually disaggregated primary and metastatic tumor samples 
(n=84). The proportion of CD3+ TIL among live cells recovered varied widely among 
samples (median 3%, range 0.1%-20%) (Figure 28A). Infiltration by NK cells was overall 
less (median 1% range 0.1%-35%) (Figure 28A).  However, CD3+ TIL were a significantly 
greater portion of the infiltrate than NK cells in most cases (p<0.0001). 
  Because TIL ACT for OvCa would most likely target patients who progressed on 
standard of care and thus would be administered to chemo-refractory patients likely to be 
metastatic, the contribution of those parameters on the T-cell infiltration was investigated. 
When patients were stratified by chemotherapy exposure and surgery site, metastatic tumors 
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were found to have more CD3+ TIL than primary tumors (median 4% vs. 1.5%, p=0.029) as a 
component of live cells (Figure 28B). No significant difference in the proportion of CD3+ 
TIL was found between pre-chemotherapy and post-chemotherapy samples (Figure 28C).  
Within the CD3+ TIL compartment, the mean CD8:CD4 ratio was 1.5 demonstrating 
that OvCa is predominately infiltrated by CD8+ TIL (Figure 28D). No difference in the 
CD8:CD4 ratio was found in the context of primary/metastasis and pre/post-chemotherapy 
(Figure 28E and 28F). As a point of comparison, both the CD3+ TIL infiltration and 
CD8:CD4 ratio were found to be similar to what our group has previously reported in 
metastatic melanoma [252], suggesting that OvCa tumors are relatively well infiltrated by T 
cells.   
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(A) T cell (CD3+) and NK cell (CD3-CD56+) infiltration is compared within the live 
lymphocyte population using flow cytometry, with the horizontal bar representing the median 
value of each population (n=84). T cell (CD3+) infiltration is compared between (B) primary 
and metastatic sites, and (C) pre- and post-chemo samples, with the horizontal bars 
indicating the median value (n=84). (D) The ratio of CD8+% to CD4+% T cells within the 
CD3+ compartment is displayed. The dotted line indicates where a ratio of 1 is in relation to 
the average ratio which is represented by the solid horizontal line (n=72). The CD8/CD4 
ratio is compared between (E) primary and metastatic sites and (F) pre- and post-chemo 
samples, with the horizontal bars indicating the median value (n=72). Samples that had less 
than 100 cells within the CD8 and CD4 gates were excluded from analysis. 
 
5.2.2 Use of agonistic 4-1BB mAb and anti-CD3 increases TIL growth and success rate  
Prior work by our group detailed how infusion of melanoma patients with a higher 
proportion of CD8+ T cells and larger amount of TIL in general correlates with clinical 
response [95, 108]. It was reasoned that CD8+ TIL could also be important in other solid 
tumor types as their presence correlates with improved survival. Thus, the two new 
methodologies, which aimed at facilitating the expansion of CD8+ TIL from ovarian cancer 
tissue, were tested next (Figure 29). 
Fresh tumor samples were set up for TIL culture using the different expansion 
methods. The first method compared IL-2 only versus IL-2 plus an agonistic 4-1BB mAb 
(a41BB). Use of a41BB significantly increased the average total CD3+ TIL growth from 
30x106 cells for IL-2 alone to 50x106 for IL-2 + a41BB (Figure 29A). Additionally, a41BB 
greatly increased the average percentage of CD8+ TIL in culture from 30% for IL-2 alone to 
65% for IL-2 + a41BB (Figure 29B). A corresponding decrease in the average percentage of 
CD4+ TIL from the IL-2 only condition to the IL-2 + a41BB condition was also observed 
(Figure 30). The mean CD4+ percentage dropped from 50% to 5% (Figure 30A) and the 
median CD8-to-CD4 ratio increased from 0.4 to 60 respectively (Figure 30B).  
Figure 28. Characterization of lymphocyte infiltrate in primary/metastatic and 
pre/post-chemo OvCa samples. 
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Comparison of the (A) total CD3+ TIL number, (B) percentage of CD3+CD8+ TIL, and (C) 
percentage of NK cells generated between the different culture methods. Samples in IL-2 and 
IL-2+a41BB conditions are paired (n=30) while samples in IL-2+OKT3+a41BB are unpaired 
(n=36). For (A), (B), and (C), only samples that grew are shown. Some samples are not 
shown due to dropout after QC. The horizontal bars indicate the mean value and SD are 
shown for each population. Comparison between culture methods of the (E) time of culture 
and (E) success rate of growth for all attempted cultures. In E, IL-2+a41BB has 55 samples 
because one sample was set up without an IL-2 only counterpart culture.  
 
 
 
 
 
Figure 29. Characterization of OvCa TIL growth across culture conditions. 
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Figure 30. Characterization of OvCa CD4+ TIL growth. 
Comparison between the different culture conditions of (A) percentage of CD4+ TIL and (B) 
the %CD8+/%CD4+ ratio from successful cultures. For (A), The horizontal bars indicate the 
mean value and SD, and in (B) the horizontal bars indicate the median value.  
 
However, since NK cells can also express 4-1BB, the addition of the a41BB mAb 
increased their growth as well from 15% to 40% of the expanded culture on average (Figure 
29C). To avoid expansion of NK cells, a 3rd culture strategy using an agonistic stimulation of 
CD3 with an anti-CD3 mAb (OKT3) was implemented. Similar to previous work for 
metastatic melanoma TIL expansion, this strategy (named TIL 3.0) led to a high percentage 
of CD8+ TIL (80% average, Figure 29B) with a low percentage of CD4+ TIL (10% average, 
Figure 30), and NK cells (5% average, Figure 29C) [218]. Protocol-induced changes in CD4+ 
Tregs were not assessed due to prior observations that high-dose IL-2 does not allow Treg 
growth and abrogates their function [243, 302]. To show the benefit of a41BB, a sub-set of 
10 samples were cultured with IL-2 + OKT3 (no a41BB) and compared with TIL 3.0 (Figure 
31). Without a41BB, the total number of CD3+ TIL and the percentage of that which were 
CD8+ TIL were both diminished while NK cells remained low (Figure 31A).  
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TIL 3.0 also produced a greater number of OvCa TIL (mean of 200x106 cells) after a 
period of 2-3 weeks, as opposed to the 3-5 weeks required for the other two methods (Figure 
29A and 29D). The consistent reduction in culture time was lost when IL-2 + OKT3 without 
a41BB was used and the yield of TIL was inferior (Figure 31B). The time of expansion did 
not appear to depend on chemotherapy exposure (Figure 32A), although CD3+ TIL from 
post-chemotherapy samples grew slightly, but significantly, less (225x106 vs. 200x106, 
p=0.028) using TIL 3.0 (Figure 32B). Regardless, all TIL 3.0 cultures produced markedly 
more TIL than IL-2 only or IL-2+a41BB.  
 
Figure 31. Characterization of OvCa TIL growth using IL-2+OKT3 without a41BB. 
Comparison of (A) total CD3+ TIL number, percentage of NK cells, percentage of 
CD3+CD8+ TIL, and CD3+CD4+ TIL between IL-2+OKT3 and TIL 3.0. Only samples where 
both conditions produced TIL are shown (n=8). The horizontal bars indicate the mean value 
and SD is shown for each population. Comparison of the (B) time of culture and success rate 
between culture methods (n=10 for both). 
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Comparison of (A) the days in culture, (B) total CD3+ TIL growth, and (C) growth success 
rate for all three conditions between pre- and post-chemotherapy samples. (A) and (C) show 
all attempted cultures and (B) shows only cultures that grew. In (B), the horizontal bars 
indicate the mean value and SD are shown for each population. 
 
The overall success rate of establishing an OvCa TIL culture was greatly increased 
from 41% (22/54) for IL-2 only and 76% (42/55) for IL-2+a41BB to 95% (41/43) for the IL-
2+OKT3+a41BB method (Figure 29E). The benchmark for a successful TIL culture, 12x106 
total cells, was established from scaling down the MDACC Clinical Melanoma TIL Lab’s 
criterion for success where 20 fragments are set up for TIL expansion and 40x106 cells is 
considered the minimum to treat a patient [252]. Chemotherapy exposure only affected the 
success rate of expansion for the IL-2 only condition, with the success being 45% (13/29) for 
Figure 32. Chemotherapy exposure does not affect OvCa TIL growth. 
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pre-chemotherapy and 36% (9/25) for post-chemotherapy (Figure 32C). This discrepancy 
was negated for the IL-2+a41BB and TIL 3.0 methods.  
It was assessed if the presence of TIL in the fresh sample affected the success of 
growth (Figure 33). When comparing the percentage of CD3+ TIL in the fresh sample vs the 
number grown, there was a strong correlation (rS > 0.5) for the IL-2 only culture method 
where more CD3+ TIL grew if there were a higher percentage of CD3+ TIL present in the 
initial tumor tissue (Figure 33A). Moreover, it was apparent that cultures with less than 2% 
CD3+ TIL in the initial tumor tissue cultured with IL-2 alone did not grow, but cultures 
initiated with as little as 0.2% CD3+ T-cell infiltrate could yield appreciable number of TIL 
when cultured with IL-2+OKT3+a41BB. However, while the IL-2+a41BB and TIL 3.0 
culture conditions did not show as strong of a correlation with T-cell infiltration (rS < 0.5), 
the overall trend was the same as indicated by the positive slopes of the linear regression 
lines (Figure 33A). There was no strong correlation with respect to the CD8+/CD4+ ratio of 
fresh TIL and the amount of CD8+ TIL generated, particularly for the IL-2 only condition 
due to the lack of CD8+ TIL generated by this method (Figure 33B). Overall, there was a 
positive trend towards growing more CD8+ TIL if there was a higher CD8+/CD4+ ratio 
initially as indicated by the slopes of the regression line for IL-2+a41BB and IL-
2+OKT3+a41BB.  
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(A) Comparison between %CD3+ TIL (in live cell population) in fresh sample versus the 
total CD3+ TIL grown for IL-2 only (red), IL-2+a41BB (blue), and TIL 3.0 (black). The 
dashed vertical line indicates the cutoff at which IL-2 cultures don’t grow if initial CD3% is 
<2%. (B) Comparison between %CD8/%CD4 ratio in fresh sample versus the total CD8+ TIL 
grown for each condition. Each sample is paired between the fresh sample and the TIL 
number generated from the same sample. rS = Spearman correlation coefficient, p value is for 
the significance of the correlation, m = slope of the linear regression line (solid lines that 
represent general trend of the population).  
 
 
Figure 33. Correlation between amount of OvCa TIL present in fresh tissue and 
magnitude of TIL growth. 
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5.2.3 Concurrent engagement of 4-1BB and CD3 prevents CD8+ TIL over differentiation 
To understand how the different culture methods affected the CD8+ TIL, the 
expression of CD28, BTLA, and PD-1 expression were explored as surrogates for T-cell 
activation and differentiation (Figure 34). These 3 markers were strategically selected for the 
power of assessment they provide individually as well as together. BTLA+CD8+ TIL have 
been reported by our group to be less-differentiated cells, capable of prolong persistence and 
serial killer capacities [188, 189]. Expression of CD28 is also a trait of lesser differentiation, 
while PD1 is often associated with exhaustion when highly expressed [249, 253]. When 
looking at expression of the 3 markers on OvCa TIL expanded with IL-2 only and IL-
2+a41BB, no significant difference was observed between both groups. Nonetheless, both 
showed a spread in CD28 and PD1 expression (Figure 34, left and right graph) with a low 
expression of BTLA (Figure 34, middle graph). However, TIL products grown with the TIL 
3.0 method had significantly greater percentage of TIL expressing BTLA and CD28, and a 
significantly smaller percentage expressing PD-1 altogether suggesting a less differentiated 
profile (Figure 34).  
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Comparison between the different culture methods of the percentage of CD28, BTLA, and 
PD-1 expressing CD8+ TIL generated. Samples in IL-2 and IL-2+a41BB conditions are 
paired (n=28) while samples in IL-2+OKT3+a41BB are unpaired (n=25). Samples not 
passing QC were excluded from analysis. The horizontal bars indicate the mean value and 
SD are shown for each population. 
 
5.2.4 OvCa CD8+ TIL show HLA-matched tumor reactivity  
In order for TIL ACT to be an effective therapy, the TIL generation process needs to 
expand anti-tumor T cells. Since the three different growth methods used could potentially 
change the expanded TIL repertoire, tumor reactivity was used as a marker to validate 
preservation of tumor-reactive TIL clones. Since our main focus is reactivity of cytotoxic 
CD8+ T cells, each TIL line was sorted for CD8+ TIL and further expanded using the rapid 
expansion protocol to achieve sufficient cell numbers. Eight TIL lines were chosen to assess 
HLA-matched tumor reactivity that were representative of the different culture methods, 
surgery sites, and prior chemotherapy exposure, which is summarized in Table 4.  
Figure 34. Phenotyping of activation and differentiation of grown OvCa TIL. 
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Table 4. Tumor targets for each TIL line and the HLA alleles for which they match. 
 
For the first set of four lines, reactivity was assessed comparing initial growth with 
IL-2 only or IL-2+a41BB (Figure 35A). The second set of four lines had reactivity compared 
between those expanded with IL-2+a41BB or with TIL 3.0 (Figure 35B). Prior to co-culture 
setup, all tumor lines were found to express robust levels of HLA class I by flow cytometry 
(SKOV3, MFI: 2962; COV318, MFI: 5343; COV362, MFI: 2182; Figure 36). As shown in 
Figure 35A, upon co-culture of the CD8+ TIL with tumor targets, 2/4 of the first set (15-094 
and 16-025B) demonstrated HLA-restricted anti-tumor reactivity via secretion of IFN-γ. The 
reactivity was split between one line grown with IL-2+a41BB (15-094) and one with IL-2 
only (16-025B). Likewise, in Figure 35B, 3/4 of the second set of TIL lines were reactive 
against their HLA-matched target. One TIL line (18-121) even recognized two different 
tumor lines. Two TIL lines in this group (17-309 and 18-121) showed reactivity regardless of 
culture method while one showed reactivity only from TIL grown with IL-2+a41BB (17-
378). Overall, TIL recognition of HLA-matched tumor targets was observed across the 
multiple expansion platforms.  
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Figure 35. Testing reactivity of CD8+ OvCa TIL via IFN-γ ELISPOT. 
(A) Comparison of reactivity of TIL grown with either IL-2 only (red) or IL-2+a41BB (blue) 
for four different lines, with a representative ELISPOT image shown. (B) Comparison of 
reactivity of TIL grown with either IL-2+a41BB (blue) or IL-2+OKT3+a41BB (white) for 
four different lines, with a representative ELISPOT image shown. Bar graphs show average 
of 3 replicate wells with the SD and average spot value for each condition above the bars. 
Reactivity was considered positive if the average was ≥ twice the xMHC condition. xMHC = 
MHCI block, Iso = isotype control for MHCI blocking Ab, TIL only = T cells with media 
only, PMA/Iono = PMA and Ionomycin for positive control, TNTC = too numerous to count.  
 
 
 
Figure 36. HLA-ABC expression of OvCa cell lines. 
The expression of MHCI alleles A, B, and C is shown in comparison to an unstained control. 
The mean fluorescence intensity (MFI) is shown in the legend to indicate the magnitude of 
expression.  
 
 
 
 
 
 
109 
 
5.3 Summary for OvCa TIL 
 
It was observed that OvCa has a robust and activated CD8+ TIL infiltrate that is not 
significantly impacted by surgery site or resistance to chemotherapy. This infiltrate is greatly 
expanded with the addition of an agonistic 4-1BB mAb to the TIL culture. Furthermore, 
specific growth of CD3+CD8+ TIL is augmented by adding the anti-CD3 Ab OKT3.  The 4-
1BB mAb alone and together with OKT3 consistently improved the success rate of reaching 
a clinically relevant number of TIL. Finally, OvCa CD8+ TIL derived with either culture 
method showed tumor recognition via IFN-γ secretion in response to HLA-matched ovarian 
cancer cell lines. These results suggest that enhanced culture method can facilitate TIL ACT 
for OvCa by increasing the yield of a TIL product containing anti-tumor CD8+ T cells 
regardless of primary or metastatic site, and in a chemotherapy refractory setting. 
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Chapter 6: Discussion 
 
 Immunotherapy has drastically remodeled the landscape of cancer therapy by 
harnessing the power of our own immune system. The most prominent example of this is the 
development of checkpoint blockade therapy, which inhibits immune regulatory checkpoints 
in order to reinvigorate anti-tumor T cell activity. This concept has delivered great 
improvements in terms of response rates and survival to several solid tumor types such as 
advanced melanoma, non-small cell lung cancer, renal cell carcinoma, and all MSI-high 
cancers. While much success has been found for these cancer types, which are often highly 
immunogenic [206-208], there are many others (e.g. pancreatic, ovarian, breast, MSS 
colorectal, prostate cancers) which have not yet derived benefit even though they are in great 
need of improved therapy options. Given the heterogeneity of cancers, the immune 
contexture of some tumor types may not be conducive to CBI which relies on in vivo 
manipulation of the immune response. Therefore, certain tumors may benefit most from an 
immunotherapy that approach the issue from another angle such as TIL-based ACT.  
TIL ACT can take advantage of antigen-specific TIL by expanding them ex vivo in an 
environment conducive to their activation and proliferation. TIL ACT has already found 
success in metastatic cutaneous melanoma where it provides overall response rates around 
40-50% [94, 95, 109, 152, 238]. Despite the lack of efficacy of CBI for several of these 
cancer types (pancreatic, ovarian, breast, MSS colorectal, prostate), there is still evidence for 
the role TIL in control of these tumors [27]. Therefore, the success of TIL ACT in melanoma 
could be translated to other tumor types. As such, in this dissertation, I sought to assess the 
feasibility of this therapy in other solid tumors that still have an unmet need. Specifically, I 
was guided by the hypothesis that tumor-specific TIL exist in solid tumors beyond melanoma 
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and their potential for tumor clearance can be harnessed through TIL ACT. In order to 
address this question, pancreatic ductal adenocarcinoma (PDAC) and high-grade serous 
ovarian cancer (OvCa) were chosen as models. Both PDAC and OvCa are often diagnosed at 
a late stage and face poor prognoses with 5 year survival rates of <10% and 28% 
respectively. CBI has failed to provide improved clinical benefit for either [209-211, 294, 
295]. Therefore, patients still rely on surgery and/or chemotherapy as treatment options, but 
the majority recur due to the limited effectiveness. Despite the lack of efficacy for CBI so far 
in PDAC and OvCa, the presence of T cells in the tumor tissue (TIL) is correlated with 
increased survival in both [85, 216, 290, 291]. Therefore, over the course of investigating 
transposing TIL ACT to PDAC and OvCa, I determined that both harbored tumor-reactive 
CD8+ TIL that could be expanded ex vivo for the potential application of TIL ACT. I also had 
the opportunity to improve the TIL expansion to increase the feasibility for PDAC and OvCa 
by using the three core signals needed to proper T-cell expansion and activation. Finally, I 
was able to use single-cell RNA sequencing to deeply interrogate the heterogeneity of PDAC 
TIL in an unbiased manner. This analysis revealed a potentially prognostically relevant TIL 
population as well as showing that the improved culture process expanded the high-
frequency and activated T cell clones. In this chapter, these results will be discussed within 
the greater context of the field as well as potential future directions. 
Understanding the TIL compartment of a tumor type is key to assessing the feasibility 
of TIL ACT as success is likely to rely, in part, on the quantity and quality of TIL present. 
Flow cytometry analysis provided insight into the general makeup of the TIL component 
while helping to highlight the heterogeneity of cancers. Given the classification of PDAC as 
an immunologically “cold” tumor compared to melanoma, it was no surprise to find the level 
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of CD3+ TIL infiltration was significantly less. However, it was interesting to note that the 
CD3+ TIL component was primarily composed of CD4+ TIL, which has been reported by 
others [303, 304]. Given that response to anti-PD1 CBI is correlated with increased CD8+ 
TIL at baseline, potentially the lack of response to CBI for PDAC could be attributed to the 
scarcity of CD8+ TIL [305, 306]. However, the reason for the predominance of CD4+ TIL is 
unclear.  
One potential mechanism that was elucidated in a mouse model of pancreatic cancer 
is the effect of pancreatic stellate cells (PSCs).  Activated PSCs in the surrounding stroma 
were found to sequester CD8+ TIL peritumorally via secretion of CXCL12 [307]. The same 
disparity was observed in PDAC liver metastases and could be due to the same mechanism. 
The liver also contains hepatic stellate cells (HSCs) which become activated after livery 
injury and can secrete CXCL12 as well [308]. Inhibition of the effects of stellate cells could 
be a strategy to improve the effectiveness TIL ACT. One such method could be use of 
Plerixafor (Mozobil/AMD3100) to inhibit CXCR4, the receptor for CXCL12, thus 
preventing T-cell exclusion in the tumor [309, 310]. Another potential option is 
administration of the antifibrotic compound halofuginone, which has been shown to inhibit 
PSC activation in addition to making the TME more amenable to immune infiltration by 
reducing the tumor stromal content [311, 312]. 
In addition to cellular mechanisms of CD8+ TIL exclusion, genomic factors could be 
important as well. Several groups have conducted genomic analyses and identified different 
molecular subtypes of PDAC [313-317]. Furthermore, meta-analysis of these studies resulted 
in a putative consensus nomenclature where there are two broad types of PDAC: Squamous-
like and Classical-Pancreatic. The Classic-Pancreatic is further subdivided into an Exocrine-
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like type, Classic-Progenitor type, and an Immunogenic type [318]. Based on these analyses, 
the majority of PDAC cases have a poor immune signature as well as poor prognosis 
compared to the immunogenic subtype. The fact that PDAC has a low mutation burden 
overall and the majority of PDAC subtypes are weakly immunogenic could explain the lack 
of CD8+ TIL component. Moreover, understanding of these molecular subtypes could help 
guide selection of those patients that would have a better chance to respond.  
Despite the low amount of CD8+ TIL infiltration in PDAC, further phenotyping 
shows that these CD8+ T cells found in the fresh tumors bear an activated phenotype, 
suggesting anti-tumor activity. The low percentage of CD45RA (10% ± 6%) in combination 
with the CD28 (50% ± 20%) and PD-1 expression (45% ± 12%) suggests the population is 
mainly effector memory with low to no terminally differentiated cells [319]. In order to dive 
deeper into PDAC TIL populations, initial bulk TCR-sequencing of the T cells found in the 
blood, tumor, and normal adjacent tissue was performed. TCR-sequencing allows for 
analysis of the repertoire of a T cell population. As laid out in section 1.1.3 of the 
Introduction, antigen-specific T cell clones will expand at the tumor site if they recognize 
their target. TCR-sequencing showed that 5/6 PDAC samples sequenced showed enrichment 
of select T cell clones at the tumor in comparison to the blood, suggestive of an immune 
response. This data corroborates work by Poschke et al. which also found that the T-cell 
repertoire in primary PDAC tumors was enriched versus the blood [303]. Only a subset of the 
T-cell clones found in the blood are found in the tumor, and the frequency of a clone in the 
blood does not correlate with its frequency in the tumor tissue. Furthermore, T-cell clones 
found both in the tumor and in adjacent uninvolved tissue tended to be present at higher 
frequency in the tumor tissue than the uninvolved, suggesting local proliferation or active 
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enrichment, again indicative of an anti-tumor immune response (Figure 9). However, while 
looking particularly at the high-frequency clones shared between the tumor tissue and 
adjacent uninvolved tissue, four patients exhibited similarity between the frequencies of 
shared TIL clones. This was highlighted by the fact that the top clones appeared to cluster 
along the 1:1 frequency line, suggesting that high frequency clones were shared between the 
tumor and adjacent uninvolved tissue (Figure 9). A possible explanation of this would be the 
contribution of a local immune response as opposed to a systemic one coming from the 
blood. This potentially indicates participation of tissue-resident memory T cells. 
The idea of the participation of TRM cells in an immune response for PDAC was 
particularly intriguing given then wealth of recent data suggesting this population of cells 
harbors tumor-reactive T cells or are correlated with improved survival in several tumors 
types, including potentially pancreatic cancer [262, 264-267, 320]. Given the complexity and 
variability of not only the TRM cell phenotype, but other TIL populations as well, scRNAseq 
was employed to assess the phenotypes in an unbiased manner. scRNAseq of 6 PDAC 
samples revealed four CD8+ TIL groups (CD8_C1 EOMES, CD8_C2 ZNF683, CD8_C3 
GZMB, and CD8_C4 STAT1) and three CD4+ groups (CD4_C1 TCM, CD4_C2 Treg, and 
CD4_C3 TEM). While initial flow cytometry analysis indicated that the majority of CD8+ TIL 
were effector memory cells, scRNAseq revealed the true heterogeneity of this TEM population 
that would have otherwise gone unnoticed. Of particular note is the CD8_C2 ZNF683 group 
which appears to be a TRM-like group based on the expression of ZNF683, CD69, and IL-7R 
as well as the lack of expression of KLF2, S1PR5, and ZEB2 as reported in the literature 
[254, 278]. Interestingly this population does not have high expression of ITGAE (aka 
CD103) or checkpoint molecules which have also been repeatedly reported in the literature 
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for the TRM population. This could be an indication of a unique phenotype for PDAC TRM 
cells or a reflection of T cell anergy given the reported lack of proper T-cell stimulation 
which is reported to be necessary for CD103 upregulation [271, 304, 321, 322]. A recent 
report found that expression of ZNF683 and IL7R was associated with persistence of infused 
TIL clones in the peripheral blood of a treated colorectal cancer patient after TIL therapy 
[323]. This correlation suggest that the subset cells found within our CD8_C2 ZNF683 group 
may also have increased persistence in PDAC patients treated with TIL therapy. The results 
presented in this study coupled with the data in this dissertation point to the potential benefit 
of using scRNAseq to track TIL populations from tumor resection to infusion product to 
post-treatment in order improve TIL ACT for solid tumors. Finally, another phenotypic 
feature of note for the CD8_ZNF683 population is the expression of XCL1, which has been 
shown to be important for recruiting cross-presenting DCs as well as stabilizing their 
interaction with CD8+ T-cells [324]. It’s possible then that this subpopulation not only 
participates in the immune response but also helps propagate it. 
The other two major CD8 effector cell populations, CD8_EOMES and CD8_TBET 
appear to be on opposite ends of the spectrum based expression of EOMES and TBX21 (aka 
TBET). The CD8_TBET appears to be a full-fledged cytotoxic effector population based on 
expression of the cytotoxic T cell markers GZMB, NKG7, GNLY and PRF1 while 
CD8_EOMES merely appears to be an activated CD8 TIL population based on expression of 
MHCII genes, MIP1-b and GZMK. The key to distinguishing their fate lies with the 
differential expression of the EOMES and TBX21, which are important transcription factors 
for determining the balance between terminal differentiation of effector cells and the self-
renewal of central memory cells. It has been shown that CD8+ T cells expressing EOMES are 
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able to compete the memory cell niche and lacking EOMES results in defective long-term 
persistence and secondary expansion after rechallenge [325]. On the other side of the coin, 
expression of TBX21 is known to drive differentiation of effector T cells instead of central-
memory T cells [326]. This brings up a potential model where the CD8+ effector T cells go 
down one differentiation path to the CD8_ZNF683 TRM population or down a different path 
which splits into either the cytotoxic, short-lived CD8_TBET population or the 
CD8_EOMES population that leads to more effector memory cells or recirculation of central 
memory cells. This is potentially supported by integration of the TCR sequencing shown in 
the CD8+ TIL Circos plot (Figure 23). Expanded TCR clones, which are clustered at the 5 
o’clock and 11 o’clock positions, tended to be found in multiple transcriptomic populations 
instead of staying within one cluster. This could indicate that some of the clones are 
expanded due to differentiation into the different subtypes, particularly those at the 5 o’clock 
position where the CD8_EOMES population is concentrated. Altogether, the scRNAseq data 
reveals an interesting insight into the dynamic cycle of CD8+ TIL participating in an immune 
response.  
On the other side of the T-cell coin from the CD8+ TIL are the CD4+ TIL which have 
two interesting populations: CD4_Treg and CD4_TEM. The Treg population had distinct 
expression of GITR, OX40, TIGIT, CD39, and 4-1BB, which are known to be expressed by 
activated Tregs. However, their most intriguing feature is their expression of IL32 which is 
nominally a pro-inflammatory cytokine and does not seem to fit with the immunosuppressive 
function of Tregs [327]. In fact, there does not appear to be any literature linking secretion of 
IL-32 to Tregs. Instead, there are several reports on the effects of IL-32 in other contexts that 
could give clues to role of IL-32 secreting Tregs. It has been shown to induce expression of 
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the immunosuppressive factors IDO and ILT4 in macrophages, DCs, and Tregs [327]. As a 
result, in the context of HIV, it can actually dampen the antiviral immune response [328]. 
Additionally, IL-32 can induce IL-6 production which is associated with a more metastatic 
phenotype in pancreatic cancer [329]. Since little is known about the role of IL-32 expressing 
Tregs, this could serve as a novel Treg population worthy of exploration in pancreatic cancer.  
The other CD4 population, CD4_TEM is potentially interesting given its activated 
phenotype, particularly its expression of IL-2 and CD40LG, the ligand for CD40. Interim 
results for an ongoing clinical trial using chemotherapy plus an agonistic CD40 mAb with or 
without anti-PD1 (Nivolumab) has shown very promising results: the ORR among 30 
patients has been greater than 50% [330]. Given this data, it’s conceivable that an activated 
CD40LG+CD4+ T cell population could engage CD40 on antigen-presenting cells and help 
effector T cell activation to ultimately provide some clinical benefit. Apart from activating 
CD4 T cells, an agonistic OX40 mAb can abrogate Treg suppression [62]. Therefore, one 
possibility could be the addition of an agonistic OX40 mAb to target the CD4_TEM 
population while simultaneously depleting the highly activated OX40+ CD4_Treg population.  
Given the fact that there are TIL present with a desirable phenotype, a major step 
towards developing TIL ACT for tumor types beyond melanoma is showing the feasibility of 
TIL culture. One of the main criticisms of TIL ACT has been the length of culture needed to 
produce a cellular product ready to treat patients.  For metastatic melanoma, in which the 
therapy was pioneered, the pre-REP (fragment culture) can take up to 5 weeks using the 
“traditional” method of high-dose IL-2 in 24-well tissue-culture plates [331]. This is in 
addition to the 2 week REP process needed expand enough TIL to be able to treat a patient, 
producing a delay of up to 7 weeks. This prolonged wait time would result in some patients 
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no longer being eligible for treatment in the case of a rapid progression. This would be 
particularly true in the case of PDAC and OvCa patients, who are often dealing with late-
stage cancer, and do not have the ability to wait almost 2 months for treatment. Furthermore, 
on top of the lengthy wait time is the fact that a successful TIL culture is not guaranteed. 
Even for a highly infiltrated tumor type like melanoma, the historical success rate for a 
successful TIL culture is 60-70%, which is to say that a sufficient number of TIL was 
expanded in the pre-REP phase in order to be able to treat a patient [96, 154, 156, 332]. The 
issues of extended culture time and less-than-ideal success rate were recapitulated to even 
worse degree in attempting TIL culture for PDAC and OvCa. Using the traditional culture 
method, I observed that culture time was consistently 4-5 weeks with success rates of 29% 
for PDAC and 41% for OvCa.  In addition, this issue of prolonged TIL culture was also 
found in early OvCa TIL ACT trials using the traditional TIL culture method, which likely 
contributed to the poor results observed along with low cell numbers overall and lack of 
lymphodepletion before TIL infusion [296-300]. The question of why some PDAC and OvCa 
TIL cultures do not grow with IL-2 is still mostly an open one and several factors could be at 
play.  
PDAC is generally characterized as an immunologically “cold” tumor that is defined 
by a low T-cell infiltrate, an immunosuppressive TME, and a dense desmoplastic component 
that excludes immune cells [304]. As it has been observed by me and others, PDAC has a 
much lower TIL presence than melanoma [119, 241, 304]. The poor growth observed with 
IL-2 only could simply be a function of low T-cell infiltration that is below a threshold 
amenable to outgrowth. Another possible explanation is the presence of inhibitory immune 
cells that increase the hurdle for T cells to expand, such as the Tregs as shown in the by 
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scRNAseq and flow cytometry analysis. The inhibition of TIL in pancreatic cancer has been 
frequently attributed to the presence of Tregs [333, 334].  Likewise, other 
immunosuppressive factors within the PDAC TME such as IL-10, TGF-b, IDO, myeloid-
derived suppressor cells (MDSCs) also likely contribute [335].  
In the context of OvCa TIL culture, a lack of TIL infiltration would not seem to be an 
apparent reason for the failure of 59% of cultures as we observed that the level of infiltration 
is quite similar to melanoma. However, we did observe a correlation with a lack of TIL 
growth with IL-2 when the percentage of CD3+ TIL in the fresh tumor sample was below 2% 
(Figure 33). Due to the variability of immune infiltration in all cancers, not just OvCa, it 
stands to reason that some sample will not produce TIL outgrowth simply due to insufficient 
TIL numbers. Beyond that, a more complex cellular mechanism could be involved. Recent 
work pinpointed an inhibitory population of NK cells that could at least partially explain the 
increased difficulty to grow TIL with IL-2 in OvCa [336]. Inhibition of CD3+ TIL expansion 
was correlated with concurrent expansion of NK cells (CD3-CD56+) within IL-2 only 
cultures. Furthermore, slow-growing TIL cultures were observed to contain more NK cells 
than fast-growing cultures. While we observed that NK cells did sometimes expand at the 
expense of CD3+ TIL growth, we did not find a correlation between NK cell presence and 
lack of TIL growth. Similarly to PDAC, OvCa can harbor the same inhibitory immune 
populations like MDSCs and Tregs, as well as immunosuppressive factors like IDO that 
could contribute [337].  
Beyond the poor success rate and lengthy time of TIL culture with the traditional 
method of PDAC and OvCa TIL culture, I also observed that predominantly CD4+ TIL were 
produced as opposed to the CD8+ TIL which are correlated with response to TIL ACT. All 
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of these factors greatly reduced the feasibility of TIL ACT for PDAC and OvCa, thus the 
implementation of an improved culture method (TIL 3.0) which addressed all these issues. 
TIL 3.0 uses 4-1BB and CD3 stimulation to selectively and robustly expand CD8+ TIL with a 
95% success rate for both cancer types. The TIL 3.0 method was helpful for OvCa TIL 
culture given the fact that 4-1BB stimulation alone caused extensive NK cell proliferation in 
some cases, perhaps facilitating their ability to inhibit T-cell growth. The addition of OKT3 
to specifically trigger T-cell expansion overcomes the issue of unwanted NK cell growth. 
Overall, TIL 3.0 also allowed OvCa cultures to grow that were below the 2% live CD3+ TIL 
threshold that prevented many IL-2 only cultures from growing. Importantly, TIL 3.0 
allowed for massive CD8+ TIL proliferation in the absence of over differentiation as 
indicated by a high percentage of the TIL product expressing CD28 and BTLA, and a low 
percentage expressing PD-1.  
Apart from being a key co-stimulatory molecule for T cells, CD28 also serves as a 
measure of differentiation as it is lost as a T cells becomes more differentiated, particularly at 
the terminal differentiation stage. Loss of expression of CD28 on TIL is associated with 
weak antigen responsiveness in melanoma as well as a key factor leading to senescence, 
while maintained expression is associated with prolonged persistence in ACT patients [161, 
338, 339]. A higher percentage of BTLA expressing CD8+ TIL in the infusion product was 
correlated with persistence and response in metastatic melanoma TIL treated patients in 
previous work here at MDACC [108]. Further work by Haymaker et al. and Ritthipichai et 
al. laid out respectively a possible explanation for this by showing that, compared to CD8+ 
TIL lacking BTLA expression, BTLA+CD8+ TIL are less differentiated (“younger”) and able 
to serially kill cancer cells [188, 189]. Finally, we consistently observed that the use of TIL 
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3.0 leads to a decreased expression of PD-1 in the expanded TIL (Figures 18 and 34).  A low 
percentage of PD-1 expressing cells in the TIL product may help lower the risk for T cells 
dysfunction due to the PD-1/PD-L1 axis. These results suggest that TIL 3.0 can facilitate TIL 
ACT for OvCa and PDAC, and it could likely be applied to other cancer types, including 
melanoma.  
While producing a phenotypically desirable TIL product is important, they key result 
is demonstrating that the TIL culture process produces a large number of tumor-reactive TIL. 
CD8+ TIL were tested against tumor targets to demonstrate the anti-tumor potential.  For 
PDAC, we were able to show reactivity against two autologous tumor targets, demonstrating 
the presence of anti-tumor activity in expanded TIL, as also reported by other groups [120, 
241, 303]. Only a comparison of reactivity between IL-2 only and IL-2 + a4-1BB grown TIL 
was done for PDAC due to the lack of a good tumor target for TIL generated using TIL 3.0. 
Both TIL lines, regardless of culture method, showed anti-tumor reactivity. Interestingly, 
bulk TCR-sequencing of the TIL products revealed that the top clones detected were not 
always the high frequency TIL clones in the tumor and often were low frequency initially. 
This is notable given the fact that that the high-frequency clones within the tumor are often 
thought to be enriched due to expansion after antigen recognition in melanoma [340]. 
However, our data indicate that low-frequency TIL also have anti-tumor potential in PDAC. 
This was also observed in other GI cancers as well where mutation-reactive TIL were found 
at very low frequency [250]. The fact that there are tumor-reactive T cells clones in PDAC 
that have not undergone major clonal expansion indicates again the lack of proper 
stimulation which is likely related to the dearth of mutations and inhospitable TME.  Further 
analysis of the T-cell repertoires in IL-2 only or IL-2+a4-1BB culture conditions revealed 
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that they produced distinct repertoires. This result stands to reason given the fact that the a4-
1BB mAb selects recently antigen-activated CD8+ TIL expressing 4-1BB whereas IL-2 only 
provides a non-specific T-cell growth signal. Consistent with this premise is the observation 
that the IL-2+a4-1BB grown TIL appear to harbor a higher percentage of tumor reactive TIL 
compared to the IL-2 only grown TIL as shown by the increase in 4-1BB+ CD8+ TIL and 
IFN-g secretion. Since adding extra stimulation like a4-1BB increased CD8+ TIL growth, this 
indicates the a4-1BB grown TIL product contains a larger number of anti-tumor T cells.  
For testing OvCa TIL reactivity, well-established tumor cell lines that were at least 
partially HLA-matched to the TIL were used due to the difficulty of establishing autologous 
tumor lines. Not all the TIL lines showed reactivity against their HLA-matched tumor target, 
which could be an indication that they may recognize a private mutation specific to that 
patient as opposed to a shared TAA. Therefore, this does not preclude the fact that the 
unreactive TIL products would show anti-tumor reactivity if paired with an autologous 
target, which would be the case in the clinical setting as TIL ACT is meant to treat patients 
with autologous TIL. Similarly to PDAC, it appears that the improved culture method 
resulted in an OvCa TIL product that contained a greater number of tumor reactive TIL as 
indicated by the increased number of spots on the IFN-g ELISPOT (Figure 35). While TIL 
3.0 grown OvCa TIL showed increased number of tumor reactive cells (max 0.2% of total), it 
was less in comparison to melanoma TIL grown using the same method (max 0.8% of total) 
[218]. Further single-cell TCR sequencing was done on PDAC TIL grown with TIL 3.0, 
showing that the initial frequency of TIL in the tumor was maintained in the cultured 
product. For example, this means that high-frequency clones in the tumor were expanded and 
remained the dominant clones in the TIL product. Therefore, given the fact that tumor-
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reactive TIL can be found within the high-frequency clones in the tumor, one could assume 
that the increased reactivity of the OvCa TIL 3.0 grown cells could be coming from this 
compartment.  
In addition to TCR sequencing, transcriptomic scRNAseq was performed for TIL 3.0 
grown PDAC TIL in order to gain insight into the phenotype of the cultured TIL as well as 
from which transcriptomic cluster in the fresh samples were the TIL expanded. Not 
surprisingly, the TIL 3.0 cell product is made up predominantly of an activated CD8+ TIL 
cluster (CD8_GZMB) and a cycling cluster (CD3_cycling) that’s derived from the CD8 
cluster. A small activated CD4 cluster (CD4_OX40) and γδ T cell cluster are also present. 
With regards to the CD8+ TIL in the cultured product, it seems the four transcriptomic groups 
observed in the fresh TIL have mainly collapsed into one activated CD8 cluster. Given the 
fact that CD8+ TIL were expanded from all four groups (including the TRM-like population) 
according to TCRseq data, it remains to be seen if any of the features seen in the fresh TIL 
are still imprinted on them and would re-emerge in vivo after TIL administration. This is a 
particularly interesting question given the previously mentioned report of ZNF683 and IL7R 
expression being associated with persistence of TIL in the peripheral blood after TIL therapy 
[323]. scRNAseq could also be used to track the infused TIL for these characteristics as well 
as look for characteristics associated with persistence and trafficking to the tumor site. The 
activated CD4_OX40 cluster retained expression of CD40LG and, given the importance of 
CD4+ T cell help to CD8+ T cell function, administration of an OX40 mAb after TIL infusion 
could be beneficial.  
While the reactivity displayed gives a strong indication of the feasibility of TIL ACT, 
it can also be used as a springboard for identifying specific tumor antigens that could be 
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targeted with cellular therapy. OvCa TIL reactivity against HLA-matched tumor lines 
indicates recognition of shared TAA(s). Moreover, some of the TIL lines are matched on the 
same HLA allele. This is particularly interesting in the case of a highly prevalent HLA allele 
like HLA-A*02:01, which is shared by 20-50% of the population in the USA, Europe, and 
China [341]. Identifying the TCR specific for a shared TAA restricted to this HLA could be 
an attractive therapeutic option due to its broad applicability. Endogenous T-cell reactivity 
against various TAA has been shown in OvCa such as mesothelin [342], wild-type or 
mutated p53 [136, 343, 344], NY-ESO-1 [345], and Her2/neu [346]. The same has been done 
for PDAC TAAs such as mesothelin, survivin, NY-ESO-1 [120]. Identifying tumor-specific 
mutated antigens (neoantigens) as immunotherapeutic targets is also a big area of interest due 
to expression being restricted to only the tumor. There is some indication of the potential of 
this therapeutic avenue as showed by isolation of T cells from two OvCa patients that were 
specific for the same p53 neoantigen [136]. Likewise, neoantigen reactive TIL were found in 
9/10 GI cancer patients, including a pancreatic cancer patient [250]. The ability to target 
mutated KRAS, PDACs most prevalent driver mutation, could be possible given results 
showing response to mutant KRAS vaccines in PDAC patients as well as detection of mutant 
KRAS reactive TIL in colorectal cancer [115, 347]. In fact, a colorectal cancer patient that 
was treated with a TIL product containing mutant KRAS-specific TIL showed clinical 
efficacy [115]. While the TIL product contained TIL with other antigen-specificities, the 
KRAS-mutant specific TIL likely played a major role as indicated by the patient recurring 
after having lost expression of the HLA for which the mutant KRAS peptide was restricted. 
However, targeting neoantigens beyond a prevalently mutated genes like TP53 for OvCa 
(95% of cases) and KRAS for PDAC (94% of cases) could be challenging due to neither 
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having a high mutation burden [206]. However, therapies targeting a particular antigen could 
be difficult to use given the possibility of target antigen loss. TIL ACT could potentially 
avoid these issues by providing antigen specificity against a broad range of TAA. 
In conclusion, my work has demonstrated the feasibility of TIL ACT for PDAC and 
OvCa by showing that they harbor an activated, anti-tumor CD8+ T-cell infiltrate that can be 
robustly and reliably expanded using an improved 3-signal culture method consisting of a 
CD3 stimulation, an agonistic 4-1BB mAb, and high-dose IL-2. Additionally, these results 
show that TIL ACT for PDAC and OvCa is feasible regardless of primary or metastatic site, 
and, in the case of OvCa, in a chemotherapy refractory setting as is often the case. 
Furthermore, our understanding of the TIL heterogeneity in PDAC has been increased 
through the use of single-cell RNA transcriptomic and T-cell receptor sequencing, revealing 
novel TIL populations with potential prognostic implications. It was one of my biggest 
dreams that the results of my work could provide some benefit to patients in dire need of 
improved therapy options. So, it is with much hope and great expectation that I conclude my 
dissertation with the fact that a Phase II clinical trial partly based on this work is ongoing at 
MDACC to evaluate the feasibility of the adoptive transfer of autologous tumor-infiltrating 
lymphocytes in OvCa and PDAC. 
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